Facial B-Claim
hirsutism I-Claim
is I-Claim
one I-Claim
of I-Claim
the I-Claim
characteristic I-Claim
features I-Claim
of I-Claim
polycystic I-Claim
ovary I-Claim
syndrome I-Claim
( I-Claim
PCOS I-Claim
) I-Claim
, I-Claim
and I-Claim
this I-Claim
can I-Claim
lead I-Claim
to I-Claim
high I-Claim
levels I-Claim
of I-Claim
depression I-Claim
and I-Claim
anxiety I-Claim
. I-Claim
!LF! !LF!
Laser B-Claim
treatment I-Claim
appeared I-Claim
to I-Claim
reduce I-Claim
the I-Claim
severity I-Claim
of I-Claim
facial I-Claim
hair I-Claim
and I-Claim
time I-Claim
spent I-Claim
on I-Claim
hair I-Claim
removal I-Claim
as I-Claim
well I-Claim
as I-Claim
alleviating I-Claim
depression I-Claim
and I-Claim
anxiety I-Claim
in I-Claim
women I-Claim
with I-Claim
PCOS I-Claim
. I-Claim
!LF! !LF!
These B-Claim
findings I-Claim
suggest I-Claim
that I-Claim
ways I-Claim
of I-Claim
making I-Claim
this I-Claim
method I-Claim
of I-Claim
hair I-Claim
removal I-Claim
more I-Claim
widely I-Claim
available I-Claim
to I-Claim
women I-Claim
with I-Claim
facial I-Claim
hirsutism I-Claim
should I-Claim
be I-Claim
considered I-Claim
. I-Claim
!LF! !LF!
Despite B-Claim
considerable I-Claim
improvement I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
ovarian I-Claim
cancer I-Claim
, I-Claim
the I-Claim
optimization I-Claim
of I-Claim
efficacy I-Claim
and I-Claim
tolerability I-Claim
remains I-Claim
an I-Claim
important I-Claim
issue I-Claim
. I-Claim
!LF! !LF!
The B-Claim
TC I-Claim
regimen I-Claim
achieved I-Claim
comparable I-Claim
efficacy I-Claim
to I-Claim
the I-Claim
PT I-Claim
regimen I-Claim
but I-Claim
was I-Claim
associated I-Claim
with I-Claim
better I-Claim
tolerability I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
and I-Claim
should I-Claim
, I-Claim
therefore I-Claim
, I-Claim
be I-Claim
considered I-Claim
as I-Claim
an I-Claim
important I-Claim
alternative I-Claim
for I-Claim
standard I-Claim
first I-Claim
- I-Claim
line I-Claim
chemotherapy I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
ovarian I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
Surgery B-Claim
was I-Claim
associated I-Claim
with I-Claim
a I-Claim
short I-Claim
- I-Claim
term I-Claim
negative I-Claim
impact I-Claim
in I-Claim
some I-Claim
aspects I-Claim
of I-Claim
health I-Claim
related I-Claim
quality I-Claim
of I-Claim
life I-Claim
assessments I-Claim
but B-Claim
these I-Claim
changes I-Claim
became I-Claim
insignificant I-Claim
2 I-Claim
years I-Claim
after I-Claim
treatment I-Claim
. I-Claim
!LF! !LF!
However O
, O
CRT B-Claim
was I-Claim
associated I-Claim
with I-Claim
progressive I-Claim
deteriorations I-Claim
in I-Claim
pulmonary I-Claim
function I-Claim
in I-Claim
the I-Claim
longer I-Claim
term I-Claim
. I-Claim
!LF! !LF!
TCM B-Claim
therapy I-Claim
for I-Claim
removing I-Claim
toxic I-Claim
substance I-Claim
and I-Claim
unblocking I-Claim
meridians I-Claim
can I-Claim
improve I-Claim
the I-Claim
post I-Claim
- I-Claim
radiation I-Claim
QOL I-Claim
of I-Claim
patients I-Claim
with I-Claim
lung I-Claim
cancer I-Claim
to I-Claim
some I-Claim
extent I-Claim
. I-Claim
!LF! !LF!
Grade B-Claim
≥ I-Claim
3 I-Claim
febrile I-Claim
neutropenia I-Claim
and I-Claim
hypertension I-Claim
were I-Claim
more I-Claim
common I-Claim
with I-Claim
bevacizumab I-Claim
- I-Claim
containing I-Claim
therapy I-Claim
. I-Claim
!LF! !LF!
Combining B-Claim
bevacizumab I-Claim
with I-Claim
docetaxel I-Claim
and I-Claim
trastuzumab I-Claim
did I-Claim
not I-Claim
significantly I-Claim
improve I-Claim
investigator I-Claim
- I-Claim
assessed I-Claim
PFS I-Claim
. I-Claim
!LF! !LF!
Vinorelbine B-Claim
prolongs I-Claim
survival I-Claim
and I-Claim
improves I-Claim
quality I-Claim
of I-Claim
life I-Claim
in I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
non I-Claim
- I-Claim
small I-Claim
- I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
. I-Claim
!LF! !LF!
Some B-Claim
studies I-Claim
have I-Claim
also I-Claim
suggested I-Claim
that I-Claim
gemcitabine I-Claim
is I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
effective I-Claim
in I-Claim
such I-Claim
patients I-Claim
. I-Claim
!LF! !LF!
The B-Claim
combination I-Claim
of I-Claim
vinorelbine I-Claim
plus I-Claim
gemcitabine I-Claim
is I-Claim
not I-Claim
more I-Claim
effective I-Claim
than I-Claim
single I-Claim
- I-Claim
agent I-Claim
vinorelbine I-Claim
or I-Claim
gemcitabine I-Claim
in I-Claim
the I-Claim
treatment I-Claim
of I-Claim
elderly I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim
!LF! !LF!
Preparatory B-Claim
education I-Claim
and I-Claim
support I-Claim
has I-Claim
the I-Claim
potential I-Claim
to I-Claim
assist I-Claim
women I-Claim
to I-Claim
cope I-Claim
with I-Claim
cancer I-Claim
- I-Claim
related I-Claim
fatigue I-Claim
in I-Claim
the I-Claim
short I-Claim
term I-Claim
. I-Claim
!LF! !LF!
However B-Claim
, I-Claim
further I-Claim
research I-Claim
is I-Claim
needed I-Claim
to I-Claim
identify I-Claim
ways I-Claim
to I-Claim
improve I-Claim
the I-Claim
potency I-Claim
and I-Claim
sustainability I-Claim
of I-Claim
psychoeducational I-Claim
interventions I-Claim
for I-Claim
managing I-Claim
cancer I-Claim
- I-Claim
related I-Claim
fatigue I-Claim
. I-Claim
!LF! !LF!
Dysuria B-Claim
is I-Claim
common I-Claim
after I-Claim
brachytherapy I-Claim
but I-Claim
is I-Claim
typically I-Claim
mild I-Claim
. I-Claim
!LF! !LF!
Prophylactic B-Claim
alpha I-Claim
- I-Claim
blockers I-Claim
gave I-Claim
significantly I-Claim
lower I-Claim
maximum I-Claim
dysuria I-Claim
scores I-Claim
but B-Claim
did I-Claim
not I-Claim
affect I-Claim
the I-Claim
time I-Claim
to I-Claim
the I-Claim
resolution I-Claim
of I-Claim
dysuria I-Claim
. I-Claim
!LF! !LF!
The B-Claim
maximum I-Claim
IPSS I-Claim
after I-Claim
the I-Claim
implant I-Claim
was I-Claim
the I-Claim
best I-Claim
predictor I-Claim
of I-Claim
the I-Claim
resolution I-Claim
of I-Claim
dysuria I-Claim
. I-Claim
!LF! !LF!
The B-Claim
addition I-Claim
of I-Claim
bevacizumab I-Claim
to I-Claim
paclitaxel I-Claim
improved I-Claim
progression I-Claim
- I-Claim
free I-Claim
survival I-Claim
( I-Claim
PFS I-Claim
) I-Claim
of I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
breast I-Claim
cancer I-Claim
( I-Claim
MBC I-Claim
) I-Claim
. I-Claim
!LF! !LF!
The B-Claim
addition I-Claim
of I-Claim
gemcitabine I-Claim
to I-Claim
PB I-Claim
was I-Claim
not I-Claim
associated I-Claim
with I-Claim
a I-Claim
statistically I-Claim
significant I-Claim
improvement I-Claim
in I-Claim
ORR I-Claim
. I-Claim
!LF! !LF!
Treatment B-Claim
with I-Claim
PB I-Claim
+ I-Claim
G I-Claim
increased I-Claim
the I-Claim
incidence I-Claim
of I-Claim
severe I-Claim
neutropenia I-Claim
and I-Claim
dyspnea I-Claim
, I-Claim
although B-Claim
the I-Claim
regimen I-Claim
generally I-Claim
was I-Claim
well I-Claim
tolerated I-Claim
. I-Claim
!LF! !LF!
Erlotinib B-Claim
was I-Claim
generally I-Claim
well I-Claim
tolerated I-Claim
and I-Claim
had I-Claim
no I-Claim
negative I-Claim
impact I-Claim
on I-Claim
QoL I-Claim
in I-Claim
this I-Claim
subpopulation I-Claim
. I-Claim
!LF! !LF!
Erlotinib B-Claim
was I-Claim
effective I-Claim
and I-Claim
well I-Claim
tolerated I-Claim
in I-Claim
Asian I-Claim
patients I-Claim
, I-Claim
producing I-Claim
benefits I-Claim
consistent I-Claim
with I-Claim
those I-Claim
observed I-Claim
in I-Claim
the I-Claim
overall I-Claim
SATURN I-Claim
population I-Claim
. I-Claim
!LF! !LF!
Maintenance B-Claim
treatment I-Claim
with I-Claim
erlotinib I-Claim
appears I-Claim
to I-Claim
be I-Claim
a I-Claim
useful I-Claim
option I-Claim
for I-Claim
the I-Claim
management I-Claim
of I-Claim
Asian I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
without I-Claim
progression I-Claim
after I-Claim
first I-Claim
- I-Claim
line I-Claim
chemotherapy I-Claim
. I-Claim
!LF! !LF!
Response B-Claim
to I-Claim
gemcitabine I-Claim
treatment I-Claim
in I-Claim
APC I-Claim
is I-Claim
not I-Claim
associated I-Claim
with I-Claim
appreciable I-Claim
improvement I-Claim
of I-Claim
global I-Claim
HRQOL I-Claim
. I-Claim
!LF! !LF!
Those B-Claim
who I-Claim
respond I-Claim
to I-Claim
gemcitabine I-Claim
may I-Claim
experience I-Claim
a I-Claim
slight I-Claim
slowing I-Claim
of I-Claim
functional I-Claim
deterioration I-Claim
. I-Claim
!LF! !LF!
Patients B-Claim
with I-Claim
bone I-Claim
- I-Claim
cancer I-Claim
pain I-Claim
, I-Claim
already I-Claim
on I-Claim
opioids I-Claim
, I-Claim
obtain I-Claim
clinically I-Claim
important I-Claim
, I-Claim
additional I-Claim
pain I-Claim
- I-Claim
control I-Claim
, I-Claim
with I-Claim
regular I-Claim
oxycodone I-Claim
/ I-Claim
paracetamol I-Claim
dosing I-Claim
. I-Claim
!LF! !LF!
Seated B-Claim
exercise I-Claim
may I-Claim
be I-Claim
a I-Claim
feasible I-Claim
exercise I-Claim
program I-Claim
for I-Claim
women I-Claim
with I-Claim
advanced I-Claim
cancer I-Claim
for I-Claim
controlling I-Claim
fatigue I-Claim
and I-Claim
improving I-Claim
physical I-Claim
well I-Claim
- I-Claim
being I-Claim
. I-Claim
!LF! !LF!
The O
interventions O
offered O
dyads O
information O
and O
support O
. O
!LF! !LF!
Intermediary O
outcomes O
were O
appraisals O
( O
i O
. O
e O
. O
, O
appraisal O
of O
illness O
/ O
caregiving O
, O
uncertainty O
, O
and O
hopelessness O
) O
and O
resources O
( O
i O
. O
e O
. O
, O
coping O
, O
interpersonal O
relationships O
, O
and O
self O
- O
efficacy O
) O
. O
!LF! !LF!
The O
primary O
outcome O
was O
QOL O
. O
!LF! !LF!
Data O
were O
collected O
prior O
to O
intervention O
and O
post O
- O
intervention O
( O
3 O
and O
6 O
months O
from O
baseline O
) O
. O
!LF! !LF!
The O
final O
sample O
was O
302 O
dyads O
. O
!LF! !LF!
Repeated O
measures O
MANCOVA O
was O
used O
to O
evaluate O
outcomes O
. O
!LF! !LF!
Effects O
varied O
by O
intervention O
dose O
. O
!LF! !LF!
Most O
effects O
were O
found O
at O
3 O
months O
only O
. O
!LF! !LF!
Patient B-Claim
- B-Claim
caregiver B-Claim
dyads I-Claim
benefit I-Claim
when I-Claim
viewed I-Claim
as I-Claim
the I-Claim
' I-Claim
unit I-Claim
of I-Claim
care I-Claim
' I-Claim
. I-Claim
!LF! !LF!
To O
observe O
the O
clinical O
efficacy O
of O
Shenqi O
Fuzheng O
Injection O
( O
SFI O
) O
combined O
with O
chemotherapy O
in O
treating O
patients O
with O
advanced O
breast O
cancer O
. O
!LF! !LF!
Sixty O
patients O
were O
randomly O
assigned O
to O
two O
groups O
by O
digital O
table O
, O
the O
control O
group O
and O
the O
treatment O
group O
, O
30 O
in O
each O
group O
. O
!LF! !LF!
All O
patients O
were O
treated O
with O
the O
same O
CTF O
regimen O
of O
chemotherapy O
for O
21 O
days O
as O
one O
therapeutic O
cycle O
, O
while O
those O
in O
the O
treatment O
group O
were O
given O
SFI O
additionally O
in O
the O
meanwhite O
. O
!LF! !LF!
The O
therapeutic O
efficacy O
was O
evaluated O
after O
2 O
cycles O
of O
treatment O
by O
observing O
the O
changes O
of O
short O
- O
term O
efficacy O
, O
TCM O
syndrome O
, O
quality O
of O
life O
and O
immune O
function O
, O
as O
well O
as O
the O
adverse O
reaction O
. O
!LF! !LF!
For B-Claim
treatment I-Claim
of I-Claim
advanced I-Claim
breast I-Claim
cancer I-Claim
, I-Claim
SFI I-Claim
can I-Claim
alleviate I-Claim
the I-Claim
bone I-Claim
marrow I-Claim
inhibition I-Claim
caused I-Claim
by I-Claim
chemotherapy I-Claim
, I-Claim
improve I-Claim
clinical I-Claim
symptoms I-Claim
and I-Claim
quality I-Claim
of I-Claim
life I-Claim
and I-Claim
prolong I-Claim
the I-Claim
survival I-Claim
period I-Claim
by I-Claim
regulating I-Claim
cellular I-Claim
immune I-Claim
function I-Claim
of I-Claim
patients I-Claim
, I-Claim
so I-Claim
as I-Claim
to I-Claim
enhance I-Claim
the I-Claim
therapeutic I-Claim
effect I-Claim
of I-Claim
chemotherapy I-Claim
. I-Claim
!LF! !LF!
The O
American O
College O
of O
Surgeons O
Oncology O
Group O
phase O
III O
Surgical O
Prostatectomy O
Versus O
Interstitial O
Radiation O
Intervention O
Trial O
comparing O
radical O
prostatectomy O
( O
RP O
) O
and O
brachytherapy O
( O
BT O
) O
closed O
after O
2 O
years O
due O
to O
poor O
accrual O
. O
!LF! !LF!
We O
report O
health O
- O
related O
quality O
of O
life O
( O
HRQOL O
) O
at O
a O
mean O
of O
5 O
. O
3 O
years O
for O
168 O
trial O
- O
eligible O
men O
who O
either O
chose O
or O
were O
randomly O
assigned O
to O
RP O
or O
BT O
following O
a O
multidisciplinary O
educational O
session O
. O
!LF! !LF!
After O
initial O
lack O
of O
accrual O
, O
a O
multidisciplinary O
educational O
session O
was O
introduced O
for O
eligible O
patients O
. O
!LF! !LF!
In O
all O
, O
263 O
men O
attended O
47 O
sessions O
. O
!LF! !LF!
Of O
those O
, O
34 O
consented O
to O
random O
assignment O
, O
62 O
chose O
RP O
, O
and O
94 O
chose O
BT O
. O
!LF! !LF!
Five O
years O
later O
, O
these O
190 O
men O
underwent O
HRQOL O
evaluation O
by O
using O
the O
cancer O
- O
specific O
50 O
- O
item O
Expanded O
Prostate O
Cancer O
Index O
Composite O
, O
the O
Short O
Form O
12 O
Physical O
Component O
Score O
, O
and O
Short O
Form O
12 O
Mental O
Component O
Score O
. O
!LF! !LF!
Response O
rate O
was O
88 O
. O
4 O
% O
. O
!LF! !LF!
The O
Wilcoxon O
rank O
sum O
test O
was O
used O
to O
compare O
summary O
scores O
between O
the O
two O
interventions O
. O
!LF! !LF!
Of O
168 O
survey O
responders O
, O
60 O
. O
7 O
% O
had O
BT O
( O
9 O
. O
5 O
% O
randomly O
assigned O
) O
and O
39 O
. O
3 O
% O
had O
RP O
( O
9 O
. O
5 O
% O
randomly O
assigned O
) O
. O
!LF! !LF!
Median O
age O
was O
61 O
. O
4 O
years O
for O
BT O
and O
59 O
. O
4 O
for O
RP O
( O
P O
= O
. O
05 O
) O
. O
!LF! !LF!
Median O
follow O
- O
up O
was O
5 O
. O
2 O
years O
( O
range O
, O
3 O
. O
2 O
to O
6 O
. O
5 O
years O
) O
. O
!LF! !LF!
Although O
treatment O
allocation O
was O
random O
in O
only O
19 O
% O
, O
all O
patients O
received O
identical O
information O
in O
a O
multidisciplinary O
setting O
before O
selecting O
RP O
, O
BT O
, O
or O
random O
assignment O
. O
!LF! !LF!
HRQOL B-Claim
evaluated I-Claim
3 I-Claim
. I-Claim
2 I-Claim
to I-Claim
6 I-Claim
. I-Claim
5 I-Claim
years I-Claim
after I-Claim
treatment I-Claim
showed I-Claim
an I-Claim
advantage I-Claim
for I-Claim
BT I-Claim
in I-Claim
urinary I-Claim
and I-Claim
sexual I-Claim
domains I-Claim
and I-Claim
in I-Claim
patient I-Claim
satisfaction I-Claim
. I-Claim
!LF! !LF!
A O
multidimensional O
rehabilitation O
program O
for O
cancer O
survivors O
was O
developed O
to O
overcome O
cancer O
- O
related O
problems O
and O
to O
improve O
quality O
of O
life O
. O
!LF! !LF!
The O
two O
purposes O
of O
the O
study O
were O
to O
describe O
the O
effectiveness O
of O
the O
program O
and O
to O
obtain O
information O
about O
patient O
preferences O
for O
multi O
or O
mono O
dimensional O
rehabilitation O
programs O
. O
!LF! !LF!
cancer O
survivors O
with O
different O
diagnoses O
, O
and O
cancer O
- O
related O
physical O
and O
psychosocial O
problems O
. O
!LF! !LF!
a O
15 O
- O
week O
rehabilitation O
program O
including O
individual O
exercise O
, O
sports O
, O
psycho O
- O
education O
, O
and O
information O
. O
!LF! !LF!
Group O
- O
wise O
randomization O
was O
implemented O
by O
assigning O
one O
half O
of O
the O
patients O
to O
the O
complete O
program O
while O
the O
other O
half O
were O
allowed O
to O
choose O
which O
program O
components O
they O
considered O
relevant O
. O
!LF! !LF!
Health O
- O
Related O
Quality O
of O
Life O
[ O
RAND O
- O
36 O
and O
Rotterdam O
Symptom O
Check O
List O
( O
RSCL O
) O
] O
, O
exercise O
capacity O
( O
symptom O
limited O
bicycle O
ergometry O
) O
, O
muscle O
force O
( O
hand O
- O
held O
dynamometry O
) O
, O
and O
patient O
preferences O
. O
!LF! !LF!
Measurements O
were O
performed O
before O
( O
T0 O
) O
and O
after O
the O
rehabilitation O
program O
( O
T1 O
) O
, O
and O
at O
a O
3 O
- O
month O
follow O
- O
up O
( O
T2 O
) O
. O
!LF! !LF!
A B-Claim
multidimensional I-Claim
rehabilitation I-Claim
program I-Claim
has I-Claim
statistically I-Claim
and I-Claim
clinically I-Claim
relevant I-Claim
beneficial I-Claim
effects I-Claim
on I-Claim
health I-Claim
- I-Claim
related I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
exercise I-Claim
capacity I-Claim
, I-Claim
and I-Claim
muscle I-Claim
force I-Claim
in I-Claim
cancer I-Claim
patients I-Claim
with I-Claim
different I-Claim
diagnoses I-Claim
. I-Claim
!LF! !LF!
Furthermore O
, O
if B-Claim
offered I-Claim
the I-Claim
choice I-Claim
, I-Claim
the I-Claim
majority I-Claim
of I-Claim
cancer I-Claim
survivors I-Claim
seem I-Claim
to I-Claim
prefer I-Claim
multidimensional I-Claim
programs I-Claim
to I-Claim
programs I-Claim
with I-Claim
only I-Claim
one I-Claim
component I-Claim
. I-Claim
!LF! !LF!
Surgery O
and O
radiotherapy O
commonly O
cause O
adverse O
musculoskeletal O
problems O
, O
particularly O
loss O
of O
strength O
and O
range O
of O
motion O
, O
in O
the O
upper O
quadrant O
of O
breast O
cancer O
patients O
. O
!LF! !LF!
Few O
well O
- O
designed O
studies O
have O
investigated O
whether O
these O
impairments O
can O
be O
prevented O
. O
!LF! !LF!
Stretching B-Claim
is I-Claim
an I-Claim
effective I-Claim
technique I-Claim
for I-Claim
increasing I-Claim
range I-Claim
of I-Claim
motion I-Claim
, I-Claim
hence O
the O
aim O
of O
this O
study O
was O
to O
investigate O
whether O
a O
stretching O
program O
reduced O
acute O
musculoskeletal O
impairments O
in O
patients O
undergoing O
radiotherapy O
for O
breast O
cancer O
. O
!LF! !LF!
Sixty O
- O
four O
women O
were O
recruited O
prior O
to O
commencement O
of O
radiotherapy O
following O
breast O
cancer O
surgery O
. O
!LF! !LF!
Participants O
were O
randomised O
to O
either O
a O
control O
or O
stretch O
group O
. O
!LF! !LF!
Participants O
in O
both O
groups O
were O
reviewed O
by O
the O
physical O
therapist O
on O
a O
weekly O
basis O
for O
approximately O
6 O
weeks O
, O
and O
were O
given O
general O
information O
about O
skin O
care O
and O
lymphedema O
. O
!LF! !LF!
The O
control O
group O
received O
no O
advice O
about O
exercise O
. O
!LF! !LF!
The O
stretch O
group O
received O
instruction O
on O
low O
- O
load O
, O
prolonged O
pectoral O
stretches O
, O
which O
were O
to O
be O
performed O
daily O
and O
were O
checked O
at O
weekly O
visits O
. O
!LF! !LF!
Shoulder O
range O
of O
motion O
, O
strength O
, O
arm O
circumference O
, O
and O
quality O
of O
life O
measurements O
were O
taken O
prior O
to O
, O
and O
at O
completion O
of O
radiotherapy O
, O
and O
at O
7 O
months O
after O
radiotherapy O
. O
!LF! !LF!
Postoperative B-Claim
outcomes I-Claim
of I-Claim
patients I-Claim
undergoing I-Claim
laparoscopic I-Claim
- I-Claim
assisted I-Claim
colectomy I-Claim
( I-Claim
LAC I-Claim
) I-Claim
have I-Claim
shown I-Claim
modest I-Claim
improvements I-Claim
in I-Claim
recovery I-Claim
but I-Claim
only I-Claim
minimal I-Claim
differences I-Claim
in I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
compared I-Claim
with I-Claim
open I-Claim
colectomy I-Claim
. I-Claim
!LF! !LF!
We O
therefore O
sought O
to O
assess O
the O
effect O
of O
LAC O
on O
QOL O
in O
the O
short O
and O
long O
term O
, O
using O
individual O
item O
analysis O
of O
multi O
- O
item O
QOL O
assessments O
. O
!LF! !LF!
QOL O
variables O
were O
analyzed O
in O
449 O
randomized O
patients O
from O
the O
COST O
trial O
93 O
- O
46 O
- O
53 O
( O
INT O
146 O
) O
. O
!LF! !LF!
Both O
cross O
- O
sectional O
single O
- O
time O
and O
change O
from O
baseline O
assessments O
were O
run O
at O
day O
2 O
, O
week O
2 O
, O
month O
2 O
, O
and O
month O
18 O
postoperatively O
in O
an O
intention O
- O
to O
- O
treat O
analysis O
using O
Wilcoxon O
rank O
- O
sum O
tests O
. O
!LF! !LF!
Stepwise O
regression O
models O
were O
used O
to O
determine O
predictors O
of O
QOL O
. O
!LF! !LF!
Of O
449 O
colon O
cancer O
patients O
, O
230 O
underwent O
LAC O
and O
219 O
underwent O
open O
colectomy O
. O
!LF! !LF!
Poor O
preoperative O
QOL O
as O
indicated O
by O
a O
rating O
scale O
of O
≤ O
50 O
was O
an O
independent O
predictor O
of O
poor O
QOL O
at O
2 O
months O
postoperatively O
. O
!LF! !LF!
QOL O
variables O
related O
to O
survival O
were O
baseline O
support O
( O
P O
= O
0 O
. O
001 O
) O
and O
baseline O
outlook O
( O
P O
= O
0 O
. O
01 O
) O
. O
!LF! !LF!
Patients B-Claim
with I-Claim
poor I-Claim
preoperative I-Claim
QOL I-Claim
appear I-Claim
to I-Claim
be I-Claim
at I-Claim
higher I-Claim
risk I-Claim
for I-Claim
difficult I-Claim
postoperative I-Claim
courses I-Claim
, I-Claim
and I-Claim
may I-Claim
be I-Claim
candidates I-Claim
for I-Claim
enhanced I-Claim
ancillary I-Claim
services I-Claim
to I-Claim
address I-Claim
their I-Claim
particular I-Claim
needs I-Claim
. I-Claim
!LF! !LF!
The O
goal O
of O
this O
study O
was O
to O
assess O
the O
impact O
of O
neuronavigation O
on O
the O
cytoreductive O
treatment O
of O
solitary O
contrast O
- O
enhancing O
intracerebral O
tumors O
and O
outcomes O
of O
this O
treatment O
in O
cases O
in O
which O
neuronavigation O
was O
preoperatively O
judged O
to O
be O
redundant O
. O
!LF! !LF!
The O
authors O
conducted O
a O
prospective O
randomized O
study O
in O
which O
45 O
patients O
, O
each O
harboring O
a O
solitary O
contrast O
- O
enhancing O
intracerebral O
tumor O
, O
were O
randomized O
for O
surgery O
with O
or O
without O
neuronavigation O
. O
!LF! !LF!
Peri O
- O
and O
postoperative O
parameters O
under O
investigation O
included O
the O
following O
: O
duration O
of O
the O
procedure O
"""" O
; O
"""" O
surgeon O
' O
s O
estimate O
of O
the O
usefulness O
of O
neuronavigation O
"""" O
; O
"""" O
quantification O
of O
the O
extent O
of O
resection O
, O
determined O
using O
magnetic O
resonance O
imaging O
"""" O
; O
"""" O
and O
the O
postoperative O
course O
, O
as O
evaluated O
by O
neurological O
examinations O
, O
the O
patient O
' O
s O
quality O
- O
of O
- O
life O
self O
- O
assessment O
, O
application O
of O
the O
Barthel O
index O
and O
the O
Karnofsky O
Performance O
Scale O
score O
, O
and O
the O
patient O
' O
s O
time O
of O
death O
. O
!LF! !LF!
There B-Claim
is I-Claim
no I-Claim
rationale I-Claim
for I-Claim
the I-Claim
routine I-Claim
use I-Claim
of I-Claim
neuronavigation I-Claim
to I-Claim
improve I-Claim
the I-Claim
extent I-Claim
of I-Claim
tumor I-Claim
resection I-Claim
and I-Claim
prognosis I-Claim
in I-Claim
patients I-Claim
harboring I-Claim
a I-Claim
solitary I-Claim
enhancing I-Claim
intracerebral I-Claim
lesion I-Claim
when I-Claim
neuronavigation I-Claim
is I-Claim
not I-Claim
already I-Claim
deemed I-Claim
advantageous I-Claim
because I-Claim
of I-Claim
the I-Claim
size I-Claim
or I-Claim
location I-Claim
of I-Claim
the I-Claim
lesion I-Claim
. I-Claim
!LF! !LF!
To O
test O
the O
ability O
of O
the O
cytoprotectant O
, O
amifostine O
, O
to O
reduce O
chemoradiotherapy O
- O
induced O
esophagitis O
and O
evaluate O
its O
influence O
on O
quality O
of O
life O
( O
QOL O
) O
and O
swallowing O
symptoms O
. O
!LF! !LF!
A O
total O
of O
243 O
patients O
with O
stage O
II O
to O
IIIA O
/ O
B O
non O
- O
small O
- O
cell O
lung O
cancer O
received O
induction O
paclitaxel O
225 O
mg O
/ O
m O
( O
2 O
) O
intravenously O
( O
IV O
) O
days O
1 O
and O
22 O
and O
carboplatin O
area O
under O
the O
curve O
( O
AUC O
) O
days O
1 O
and O
22 O
, O
followed O
by O
concurrent O
weekly O
paclitaxel O
( O
50 O
mg O
/ O
m O
( O
2 O
) O
IV O
) O
and O
carboplatin O
( O
AUC O
2 O
) O
, O
and O
hyperfractionated O
radiation O
therapy O
( O
69 O
. O
6 O
Gy O
at O
1 O
. O
2 O
Gy O
bid O
) O
. O
!LF! !LF!
Patients O
were O
randomly O
assigned O
at O
registration O
to O
amifostine O
( O
AM O
) O
500 O
mg O
IV O
four O
times O
per O
week O
or O
no O
AM O
during O
chemoradiotherapy O
. O
!LF! !LF!
Beyond O
standard O
toxicity O
end O
points O
, O
physician O
dysphagia O
logs O
( O
PDLs O
) O
, O
daily O
patient O
swallowing O
diaries O
, O
and O
QOL O
( O
EORTC O
QLQ O
- O
C30 O
/ O
LC O
- O
13 O
) O
were O
also O
collected O
. O
!LF! !LF!
Swallowing O
AUC O
analyses O
were O
calculated O
from O
patient O
diaries O
and O
PDLs O
. O
!LF! !LF!
A O
total O
of O
120 O
patients O
were O
randomly O
assigned O
to O
receive O
AM O
, O
and O
122 O
, O
to O
receive O
no O
AM O
( O
one O
patient O
was O
ineligible O
) O
"""" O
; O
"""" O
72 O
% O
received O
AM O
per O
protocol O
or O
with O
a O
minor O
deviation O
. O
!LF! !LF!
AM B-Claim
did I-Claim
not I-Claim
significantly I-Claim
reduce I-Claim
esophagitis I-Claim
> I-Claim
/ I-Claim
= I-Claim
grade I-Claim
3 I-Claim
in I-Claim
patients I-Claim
receiving I-Claim
hyperfractionated I-Claim
radiation I-Claim
and I-Claim
chemotherapy I-Claim
. I-Claim
!LF! !LF!
However B-Claim
, I-Claim
patient I-Claim
self I-Claim
- I-Claim
assessments I-Claim
suggested I-Claim
a I-Claim
possible I-Claim
advantage I-Claim
to I-Claim
AM I-Claim
that I-Claim
is I-Claim
being I-Claim
explored I-Claim
with I-Claim
modified I-Claim
dosing I-Claim
route I-Claim
strategies I-Claim
. I-Claim
!LF! !LF!
The O
impact O
of O
the O
side O
effects O
of O
megestrol O
acetate O
on O
the O
quality O
of O
life O
of O
noncachectic O
women O
with O
advanced O
breast O
cancer O
was O
studied O
in O
a O
dose O
- O
response O
clinical O
trial O
of O
the O
Cancer O
and O
Leukemia O
Group O
B O
( O
CALGB O
8741 O
) O
. O
!LF! !LF!
Side O
effects O
of O
appetite O
increase O
and O
weight O
gain O
at O
higher O
doses O
were O
predicted O
to O
have O
a O
negative O
effect O
on O
quality O
of O
life O
. O
!LF! !LF!
Stage O
IV O
breast O
cancer O
patients O
were O
randomized O
to O
receive O
either O
160 O
, O
800 O
, O
or O
1 O
, O
600 O
mg O
/ O
d O
of O
megestrol O
acetate O
. O
!LF! !LF!
Quality O
of O
life O
was O
assessed O
in O
131 O
patients O
at O
trial O
entry O
and O
at O
1 O
and O
3 O
months O
while O
on O
treatment O
, O
by O
telephone O
interview O
, O
using O
the O
following O
measures O
: O
the O
Functional O
Living O
Index O
- O
Cancer O
( O
FLIC O
) O
, O
Rand O
Functional O
Limitations O
Scale O
, O
Rand O
Mental O
Health O
Inventory O
( O
MHI O
) O
, O
the O
Body O
Image O
Subscale O
, O
and O
linear O
analog O
scales O
of O
drug O
side O
effects O
. O
!LF! !LF!
Patients B-Premise
who I-Premise
received I-Premise
the I-Premise
800 I-Premise
- I-Premise
mg I-Premise
/ I-Premise
d I-Premise
dose I-Premise
fell I-Premise
between I-Premise
the I-Premise
low I-Premise
- I-Premise
and I-Premise
high I-Premise
- I-Premise
dose I-Premise
arms I-Premise
in I-Premise
reported I-Premise
intensity I-Premise
of I-Premise
drug I-Premise
side I-Premise
effects I-Premise
, I-Premise
but B-Premise
responded I-Premise
similarly I-Premise
to I-Premise
those I-Premise
in I-Premise
the I-Premise
160 I-Premise
- I-Premise
mg I-Premise
/ I-Premise
d I-Premise
group I-Premise
in I-Premise
terms I-Premise
of I-Premise
physical I-Premise
functioning I-Premise
, I-Premise
psychologic I-Premise
distress I-Premise
, I-Premise
and I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise
!LF! !LF!
Unless B-Claim
additional I-Claim
follow I-Claim
- I-Claim
up I-Claim
data I-Claim
demonstrate I-Claim
a I-Claim
survival I-Claim
advantage I-Claim
at I-Claim
higher I-Claim
doses I-Claim
, I-Claim
the I-Claim
160 I-Claim
- I-Claim
mg I-Claim
/ I-Claim
d I-Claim
dose I-Claim
is I-Claim
optimal I-Claim
, I-Claim
achieving I-Claim
maximal I-Claim
treatment I-Claim
effect I-Claim
with I-Claim
the I-Claim
fewest I-Claim
side I-Claim
effects I-Claim
and I-Claim
better I-Claim
quality I-Claim
of I-Claim
life I-Claim
. I-Claim
!LF! !LF!
Study O
Type O
- O
- O
Therapy O
( O
RCT O
) O
Level O
of O
Evidence O
1b O
. O
!LF! !LF!
What O
' O
s O
known O
on O
the O
subject O
? O
!LF! !LF!
and O
What O
does O
the O
study O
add O
? O
!LF! !LF!
Androgen O
deprivation O
therapy O
( O
ADT O
) O
is O
commonly O
used O
as O
a O
primary O
treatment O
for O
patients O
with O
prostate O
cancer O
( O
PCa O
) O
who O
are O
not O
eligible O
for O
radical O
treatment O
options O
. O
!LF! !LF!
ADT O
is O
also O
used O
in O
patients O
with O
PCa O
as O
neo O
- O
adjuvant O
hormone O
therapy O
to O
reduce O
prostate O
volume O
and O
down O
- O
stage O
the O
disease O
before O
radiotherapy O
with O
curative O
intent O
. O
!LF! !LF!
The O
present O
study O
showed O
that O
ADT O
with O
the O
gonadotropin O
hormone O
- O
releasing O
hormone O
( O
GhRH O
) O
antagonist O
degarelix O
is O
non O
- O
inferior O
to O
combined O
treatment O
with O
the O
LHRH O
agonist O
goserelin O
and O
bicalutamide O
in O
terms O
of O
reducing O
prostate O
volume O
during O
the O
treatment O
period O
of O
3 O
months O
. O
!LF! !LF!
Degarelix O
treatment O
evokes O
, O
however O
, O
significantly O
better O
relief O
of O
lower O
urinary O
tract O
symptoms O
in O
patients O
having O
moderate O
and O
severe O
voiding O
problems O
. O
!LF! !LF!
To O
assess O
the O
efficacy O
of O
monthly O
degarelix O
treatment O
for O
reduction O
of O
total O
prostate O
volume O
( O
TPV O
) O
, O
relief O
of O
lower O
urinary O
tract O
symptoms O
( O
LUTS O
) O
and O
improvement O
of O
quality O
of O
life O
( O
QoL O
) O
in O
patients O
with O
prostate O
cancer O
( O
PCa O
) O
using O
monthly O
goserelin O
as O
active O
control O
. O
!LF! !LF!
This O
was O
a O
randomized O
, O
parallel O
- O
arm O
, O
active O
- O
controlled O
, O
open O
- O
label O
, O
multicentre O
trial O
on O
182 O
patients O
treated O
with O
either O
monthly O
degarelix O
( O
240 O
/ O
80 O
mg O
) O
or O
goserelin O
( O
3 O
. O
6 O
mg O
) O
for O
12 O
weeks O
. O
!LF! !LF!
For O
flare O
protection O
, O
goserelin O
- O
treated O
patients O
also O
received O
daily O
bicalutamide O
( O
50 O
mg O
) O
during O
the O
initial O
28 O
days O
. O
!LF! !LF!
Key O
trial O
variables O
monitored O
monthly O
were O
TPV O
( O
primary O
endpoint O
) O
, O
serum O
testosterone O
, O
prostate O
- O
specific O
antigen O
( O
PSA O
) O
, O
the O
International O
Prostate O
Symptom O
Score O
( O
IPSS O
) O
and O
the O
Benign O
Prostate O
Hyperplasia O
Impact O
Index O
. O
!LF! !LF!
In O
all O
, O
175 O
patients O
completed O
the O
trial O
( O
96 O
. O
1 O
% O
) O
. O
!LF! !LF!
At B-Premise
week I-Premise
12 I-Premise
, I-Premise
changes I-Premise
in I-Premise
TPV I-Premise
for I-Premise
degarelix I-Premise
and I-Premise
goserelin I-Premise
were I-Premise
similar I-Premise
( I-Premise
- I-Premise
37 I-Premise
. I-Premise
2 I-Premise
% I-Premise
vs I-Premise
- I-Premise
39 I-Premise
. I-Premise
0 I-Premise
% I-Premise
) I-Premise
and I-Premise
met I-Premise
the I-Premise
predefined I-Premise
non I-Premise
- I-Premise
inferiority I-Premise
criterion I-Premise
. I-Premise
!LF! !LF!
Decreases B-Premise
in I-Premise
IPSS I-Premise
were I-Premise
greater I-Premise
in I-Premise
degarelix I-Premise
than I-Premise
in I-Premise
goserelin I-Premise
- I-Premise
treated I-Premise
patients I-Premise
, I-Premise
differences I-Premise
being I-Premise
statistically I-Premise
significant I-Premise
in I-Premise
patients I-Premise
with I-Premise
baseline I-Premise
IPSS I-Premise
> I-Premise
13 I-Premise
( I-Premise
- I-Premise
6 I-Premise
. I-Premise
7 I-Premise
± I-Premise
1 I-Premise
. I-Premise
8 I-Premise
vs I-Premise
- I-Premise
4 I-Premise
. I-Premise
0 I-Premise
± I-Premise
1 I-Premise
. I-Premise
0 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
The B-Premise
number I-Premise
of I-Premise
patients I-Premise
with I-Premise
an I-Premise
IPSS I-Premise
change I-Premise
of I-Premise
≥ I-Premise
3 I-Premise
over I-Premise
baseline I-Premise
was I-Premise
also I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
patients I-Premise
treated I-Premise
with I-Premise
degarelix I-Premise
( I-Premise
61 I-Premise
. I-Premise
0 I-Premise
vs I-Premise
44 I-Premise
. I-Premise
3 I-Premise
% I-Premise
, I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
Both B-Claim
treatments I-Claim
were I-Claim
safe I-Claim
and I-Claim
well I-Claim
tolerated I-Claim
. I-Claim
!LF! !LF!
Medical B-Claim
castration I-Claim
reduces I-Claim
TPV I-Claim
and I-Claim
could I-Claim
also I-Claim
improve I-Claim
LUTS I-Claim
in I-Claim
patients I-Claim
with I-Claim
PCa I-Claim
. I-Claim
!LF! !LF!
While O
the B-Claim
short I-Claim
- I-Claim
term I-Claim
efficacy I-Claim
of I-Claim
degarelix I-Claim
and I-Claim
goserelin I-Claim
+ I-Claim
bicalutamide I-Claim
was I-Claim
the I-Claim
same I-Claim
in I-Claim
terms I-Claim
of I-Claim
TPV I-Claim
reduction I-Claim
, I-Claim
degarelix B-Claim
showed I-Claim
superiority I-Claim
in I-Claim
LUTS I-Claim
relief I-Claim
in I-Claim
symptomatic I-Claim
patients I-Claim
, I-Claim
which I-Claim
could I-Claim
highlight I-Claim
the I-Claim
different I-Claim
actions I-Claim
of I-Claim
these I-Claim
drugs I-Claim
on I-Claim
extrapituitary I-Claim
gonadotrophin I-Claim
- I-Claim
releasing I-Claim
hormone I-Claim
( I-Claim
GnRH I-Claim
) I-Claim
receptors I-Claim
in I-Claim
the I-Claim
bladder I-Claim
and I-Claim
/ I-Claim
or I-Claim
the I-Claim
prostate I-Claim
. I-Claim
!LF! !LF!
To O
assess O
whether O
omission O
of O
postoperative O
radiotherapy O
in O
women O
with O
' O
low O
- O
risk O
' O
axillary O
node O
negative O
breast O
cancer O
( O
T0 O
- O
2 O
) O
treated O
by O
breast O
- O
conserving O
surgery O
and O
endocrine O
therapy O
improves O
quality O
of O
life O
and O
is O
more O
cost O
- O
effective O
. O
!LF! !LF!
A O
randomised O
controlled O
clinical O
trial O
, O
using O
a O
method O
of O
minimisation O
balanced O
by O
centre O
, O
grade O
of O
cancer O
, O
age O
, O
lymphatic O
/ O
vascular O
invasion O
and O
preoperative O
endocrine O
therapy O
, O
was O
performed O
. O
!LF! !LF!
A O
non O
- O
randomised O
cohort O
was O
also O
recruited O
, O
in O
order O
to O
complete O
a O
comprehensive O
cohort O
study O
. O
!LF! !LF!
The O
setting O
was O
breast O
cancer O
clinics O
in O
cancer O
centres O
in O
the O
UK O
. O
!LF! !LF!
Patients O
aged O
65 O
years O
or O
more O
were O
eligible O
provided O
that O
their O
cancers O
were O
considered O
to O
be O
at O
low O
risk O
of O
local O
recurrence O
, O
were O
suitable O
for O
breast O
- O
conservation O
surgery O
, O
were O
receiving O
endocrine O
therapy O
and O
were O
able O
and O
willing O
to O
give O
informed O
consent O
. O
!LF! !LF!
The O
standard O
treatment O
of O
postoperative O
breast O
irradiation O
or O
the O
omission O
of O
radiotherapy O
. O
!LF! !LF!
Quality O
of O
life O
was O
the O
primary O
outcome O
measure O
, O
together O
with O
anxiety O
and O
depression O
and O
cost O
- O
effectiveness O
. O
!LF! !LF!
Secondary O
outcome O
measures O
were O
recurrence O
rates O
, O
functional O
status O
, O
treatment O
- O
related O
morbidity O
and O
cosmesis O
. O
!LF! !LF!
The O
principal O
method O
of O
data O
collection O
was O
by O
questionnaire O
, O
completed O
at O
home O
with O
a O
research O
nurse O
at O
four O
times O
over O
15 O
months O
. O
!LF! !LF!
The B-Claim
hypothesised I-Claim
improvement I-Claim
in I-Claim
overall I-Claim
quality I-Claim
of I-Claim
life I-Claim
with I-Claim
the I-Claim
omission I-Claim
of I-Claim
radiotherapy I-Claim
was I-Claim
not I-Claim
seen I-Claim
in I-Claim
the I-Claim
EuroQol I-Claim
assessment I-Claim
or I-Claim
in I-Claim
the I-Claim
functionality I-Claim
and I-Claim
symptoms I-Claim
summary I-Claim
domains I-Claim
of I-Claim
the I-Claim
European I-Claim
Organisation I-Claim
for I-Claim
Research I-Claim
in I-Claim
the I-Claim
Treatment I-Claim
of I-Claim
Cancer I-Claim
( I-Claim
EORTC I-Claim
) I-Claim
scales I-Claim
. I-Claim
!LF! !LF!
Some O
differences O
were O
apparent O
within O
subscales O
of O
the O
EORTC O
questionnaires O
, O
and O
insights O
into O
the O
impact O
of O
treatment O
were O
also O
provided O
by O
the O
qualitative O
data O
obtained O
by O
open O
- O
ended O
questions O
. O
!LF! !LF!
Differences B-Premise
were I-Premise
most I-Premise
apparent I-Premise
shortly I-Premise
after I-Premise
the I-Premise
time I-Premise
of I-Premise
completion I-Premise
of I-Premise
radiotherapy I-Premise
. I-Premise
!LF! !LF!
Radiotherapy B-Claim
was I-Claim
then I-Claim
associated I-Claim
with I-Claim
increased I-Claim
breast I-Claim
symptoms I-Claim
and I-Claim
with I-Claim
greater I-Claim
fatigue I-Claim
but I-Claim
with I-Claim
less I-Claim
insomnia I-Claim
and I-Claim
endocrine I-Claim
side I-Claim
- I-Claim
effects I-Claim
. I-Claim
!LF! !LF!
Patients B-Premise
had I-Premise
significant I-Premise
concerns I-Premise
about I-Premise
the I-Premise
delivery I-Premise
of I-Premise
radiotherapy I-Premise
services I-Premise
, I-Premise
such I-Premise
as I-Premise
transport I-Premise
, I-Premise
accommodation I-Premise
and I-Premise
travel I-Premise
costs I-Premise
associated I-Premise
with I-Premise
receiving I-Premise
radiotherapy I-Premise
. I-Premise
!LF! !LF!
By B-Premise
the I-Premise
end I-Premise
of I-Premise
follow I-Premise
- I-Premise
up I-Premise
, I-Premise
patients I-Premise
receiving I-Premise
radiotherapy I-Premise
were I-Premise
expressing I-Premise
less I-Premise
anxiety I-Premise
about I-Premise
recurrence I-Premise
than I-Premise
those I-Premise
who I-Premise
had I-Premise
not I-Premise
received I-Premise
radiotherapy I-Premise
. I-Premise
!LF! !LF!
Functionality B-Premise
was I-Premise
not I-Premise
greatly I-Premise
affected I-Premise
by I-Premise
treatment I-Premise
. I-Premise
!LF! !LF!
Within B-Premise
the I-Premise
randomised I-Premise
controlled I-Premise
trial I-Premise
, I-Premise
the I-Premise
Barthel I-Premise
Index I-Premise
demonstrated I-Premise
a I-Premise
small I-Premise
but I-Premise
significant I-Premise
fall I-Premise
in I-Premise
functionality I-Premise
with I-Premise
radiotherapy I-Premise
compared I-Premise
with I-Premise
the I-Premise
no I-Premise
radiotherapy I-Premise
arm I-Premise
of I-Premise
the I-Premise
trial I-Premise
. I-Premise
!LF! !LF!
Results B-Premise
from I-Premise
the I-Premise
non I-Premise
- I-Premise
randomised I-Premise
patients I-Premise
did I-Premise
not I-Premise
confirm I-Premise
this I-Premise
effect I-Premise
, I-Premise
however I-Premise
. I-Premise
!LF! !LF!
Cosmetic B-Premise
results I-Premise
were I-Premise
better I-Premise
in I-Premise
those I-Premise
not I-Premise
receiving I-Premise
radiotherapy I-Premise
but B-Premise
this I-Premise
did I-Premise
not I-Premise
appear I-Premise
to I-Premise
be I-Premise
an I-Premise
important I-Premise
issue I-Premise
to I-Premise
the I-Premise
patients I-Premise
. I-Premise
!LF! !LF!
The B-Claim
use I-Claim
of I-Claim
home I-Claim
- I-Claim
based I-Claim
assessments I-Claim
by I-Claim
a I-Claim
research I-Claim
nurse I-Claim
proved I-Claim
to I-Claim
be I-Claim
an I-Claim
effective I-Claim
way I-Claim
of I-Claim
obtaining I-Claim
high I-Claim
- I-Claim
quality I-Claim
data I-Claim
. I-Claim
!LF! !LF!
Costs O
to O
the O
NHS O
associated O
with O
postoperative O
radiotherapy O
were O
calculated O
to O
be O
of O
the O
order O
of O
2000 O
pounds O
per O
patient O
. O
!LF! !LF!
In B-Premise
the I-Premise
follow I-Premise
- I-Premise
up I-Premise
in I-Premise
this I-Premise
study I-Premise
, I-Premise
there I-Premise
were I-Premise
no I-Premise
recurrences I-Premise
, I-Premise
and I-Premise
the I-Premise
quality I-Premise
of I-Premise
life I-Premise
utilities I-Premise
from I-Premise
EuroQol I-Premise
were I-Premise
almost I-Premise
identical I-Premise
. I-Premise
!LF! !LF!
Although B-Premise
there I-Premise
are I-Premise
no I-Premise
differences I-Premise
in I-Premise
overall I-Premise
quality I-Premise
of I-Premise
life I-Premise
scores I-Premise
between I-Premise
the I-Premise
patients I-Premise
treated I-Premise
with I-Premise
and I-Premise
without I-Premise
radiotherapy I-Premise
, I-Premise
there I-Premise
are I-Premise
several I-Premise
dimensions I-Premise
that I-Premise
exhibit I-Premise
significant I-Premise
advantage I-Premise
to I-Premise
the I-Premise
omission I-Premise
of I-Premise
irradiation I-Premise
. I-Premise
!LF! !LF!
Over B-Premise
the I-Premise
first I-Premise
15 I-Premise
months I-Premise
, I-Premise
radiotherapy I-Premise
for I-Premise
this I-Premise
population I-Premise
is I-Premise
not I-Premise
a I-Premise
cost I-Premise
- I-Premise
effective I-Premise
treatment I-Premise
. I-Premise
!LF! !LF!
However O
, O
the O
early B-Claim
postoperative I-Claim
outcome I-Claim
does I-Claim
not I-Claim
give I-Claim
a I-Claim
complete I-Claim
answer I-Claim
and O
the B-Claim
eventual I-Claim
cost I-Claim
- I-Claim
effectiveness I-Claim
will I-Claim
only I-Claim
become I-Claim
clear I-Claim
after I-Claim
long I-Claim
- I-Claim
term I-Claim
follow I-Claim
- I-Claim
up I-Claim
. I-Claim
!LF! !LF!
Extrapolations B-Claim
from I-Claim
these I-Claim
data I-Claim
suggest I-Claim
that I-Claim
radiotherapy I-Claim
may I-Claim
not I-Claim
be I-Claim
a I-Claim
cost I-Claim
- I-Claim
effective I-Claim
treatment I-Claim
unless I-Claim
it I-Claim
results I-Claim
in I-Claim
a I-Claim
recurrence I-Claim
rate I-Claim
that I-Claim
is I-Claim
at I-Claim
least I-Claim
5 I-Claim
% I-Claim
lower I-Claim
in I-Claim
absolute I-Claim
terms I-Claim
than I-Claim
those I-Claim
treated I-Claim
without I-Claim
radiotherapy I-Claim
. I-Claim
!LF! !LF!
Further B-Claim
research I-Claim
is I-Claim
needed I-Claim
into I-Claim
a I-Claim
number I-Claim
of I-Claim
areas I-Claim
including I-Claim
the I-Claim
long I-Claim
- I-Claim
term I-Claim
aspects I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
, I-Claim
clinical I-Claim
outcomes I-Claim
, I-Claim
costs I-Claim
and I-Claim
consequences I-Claim
of I-Claim
omitting I-Claim
radiotherapy I-Claim
. I-Claim
!LF! !LF!
A O
randomized O
controlled O
trial O
was O
performed O
to O
assess O
the O
outcome O
of O
early O
oral O
postoperative O
feeding O
( O
EOF O
) O
compared O
with O
traditional O
oral O
feeding O
( O
TOF O
) O
in O
gynecologic O
oncology O
patients O
undergoing O
a O
complex O
laparotomy O
, O
including O
upper O
abdominal O
surgery O
. O
!LF! !LF!
Patients O
aged O
18 O
- O
75 O
years O
, O
undergoing O
an O
elective O
laparotomy O
and O
with O
a O
preoperative O
suspicion O
of O
gynecologic O
malignancy O
, O
were O
eligible O
. O
!LF! !LF!
Exclusion O
criteria O
included O
infectious O
conditions O
, O
intestinal O
obstruction O
, O
severe O
malnutrition O
, O
American O
Society O
of O
Anesthesiologists O
score O
C4 O
, O
intestinal O
resection O
, O
and O
postoperative O
stay O
in O
the O
intensive O
care O
unit O
lasting O
24 O
h O
. O
Patients O
allocated O
to O
EOF O
received O
liquid O
diet O
in O
the O
first O
postoperative O
day O
and O
then O
regular O
diet O
. O
!LF! !LF!
Patients O
received O
traditional O
feeding O
scheme O
until O
resolution O
of O
postoperative O
ileus O
to O
start O
liquid O
diet O
. O
!LF! !LF!
The O
primary O
end O
- O
point O
of O
the O
trial O
was O
length O
of O
hospital O
stay O
. O
!LF! !LF!
Between O
January O
1 O
, O
2007 O
, O
and O
November O
17 O
, O
2007 O
, O
a O
total O
of O
143 O
patients O
were O
randomized O
to O
receive O
either O
EOF O
or O
TOF O
. O
!LF! !LF!
Hospital B-Premise
stay I-Premise
for I-Premise
patients I-Premise
who I-Premise
received I-Premise
EOF I-Premise
( I-Premise
n I-Premise
= I-Premise
71 I-Premise
) I-Premise
was I-Premise
4 I-Premise
. I-Premise
7 I-Premise
vs I-Premise
. I-Premise
5 I-Premise
. I-Premise
8 I-Premise
days I-Premise
for I-Premise
the I-Premise
TOF I-Premise
group I-Premise
( I-Premise
n I-Premise
= I-Premise
72 I-Premise
) I-Premise
( I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
006 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
The B-Premise
mean I-Premise
level I-Premise
of I-Premise
postoperative I-Premise
satisfaction I-Premise
was I-Premise
significantly I-Premise
higher I-Premise
in I-Premise
the I-Premise
EOF I-Premise
group I-Premise
( I-Premise
82 I-Premise
. I-Premise
8 I-Premise
vs I-Premise
. I-Premise
71 I-Premise
. I-Premise
7 I-Premise
mm I-Premise
, I-Premise
P I-Premise
B I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
Patients B-Premise
who I-Premise
received I-Premise
the I-Premise
TOF I-Premise
scheme I-Premise
had I-Premise
significantly I-Premise
higher I-Premise
overall I-Premise
postoperative I-Premise
complications I-Premise
( I-Premise
39 I-Premise
vs I-Premise
. I-Premise
17 I-Premise
% I-Premise
in I-Premise
EOF I-Premise
group I-Premise
, I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
003 I-Premise
) I-Premise
and I-Premise
infective I-Premise
complications I-Premise
( I-Premise
14 I-Premise
% I-Premise
in I-Premise
TOF I-Premise
group I-Premise
vs I-Premise
. I-Premise
3 I-Premise
% I-Premise
in I-Premise
EOF I-Premise
group I-Premise
, I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
017 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
Variables B-Premise
such I-Premise
as I-Premise
nausea I-Premise
and I-Premise
vomiting I-Premise
, I-Premise
analgesic I-Premise
and I-Premise
antiemetic I-Premise
requirement I-Premise
as I-Premise
well I-Premise
as I-Premise
level I-Premise
of I-Premise
pain I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
were I-Premise
not I-Premise
different I-Premise
between I-Premise
groups I-Premise
. I-Premise
!LF! !LF!
On B-Claim
the I-Claim
basis I-Claim
of I-Claim
these I-Claim
findings I-Claim
, I-Claim
the I-Claim
policy I-Claim
of I-Claim
EOF I-Claim
should I-Claim
be I-Claim
used I-Claim
after I-Claim
a I-Claim
complex I-Claim
gynecologic I-Claim
oncologic I-Claim
laparotomy I-Claim
. I-Claim
!LF! !LF!
Insomnia B-Claim
is I-Claim
a I-Claim
common I-Claim
complaint I-Claim
among I-Claim
cancer I-Claim
survivors I-Claim
. I-Claim
!LF! !LF!
Fortunately O
, O
cognitive O
- O
behavioral O
therapy O
for O
insomnia O
( O
CBT O
- O
I O
) O
has O
been O
shown O
to O
be O
an O
effective O
treatment O
in O
this O
population O
. O
!LF! !LF!
However O
, O
it O
is O
rarely O
implemented O
given O
its O
limited O
availability O
. O
!LF! !LF!
To O
address O
this O
barrier O
, O
we O
examined O
the O
ability O
of O
an O
easily O
accessible O
online O
CBT O
- O
I O
program O
to O
improve O
insomnia O
symptoms O
in O
cancer O
survivors O
. O
!LF! !LF!
Twenty O
- O
eight O
cancer O
survivors O
with O
insomnia O
were O
randomly O
assigned O
to O
either O
an O
Internet O
insomnia O
intervention O
( O
n O
= O
14 O
) O
or O
to O
a O
waitlist O
control O
group O
( O
n O
= O
14 O
) O
. O
!LF! !LF!
The O
online O
program O
, O
Sleep O
Healthy O
Using O
The O
Internet O
, O
delivers O
the O
primary O
components O
of O
CBT O
- O
I O
( O
sleep O
restriction O
, O
stimulus O
control O
, O
cognitive O
restructuring O
, O
sleep O
hygiene O
, O
and O
relapse O
prevention O
) O
. O
!LF! !LF!
Pre O
- O
and O
post O
- O
assessment O
data O
were O
collected O
via O
online O
questionnaires O
and O
daily O
sleep O
diaries O
. O
!LF! !LF!
Participants B-Premise
in I-Premise
the I-Premise
Internet I-Premise
group I-Premise
showed I-Premise
significant I-Premise
improvements I-Premise
at I-Premise
post I-Premise
- I-Premise
assessment I-Premise
compared I-Premise
with I-Premise
those I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
in I-Premise
overall I-Premise
insomnia I-Premise
severity I-Premise
( I-Premise
F I-Premise
( I-Premise
1 I-Premise
, I-Premise
26 I-Premise
) I-Premise
= I-Premise
22 I-Premise
. I-Premise
8 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
, I-Premise
sleep I-Premise
efficiency I-Premise
( I-Premise
F I-Premise
( I-Premise
1 I-Premise
, I-Premise
24 I-Premise
) I-Premise
= I-Premise
11 I-Premise
. I-Premise
45 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
002 I-Premise
) I-Premise
, I-Premise
sleep I-Premise
onset I-Premise
latency I-Premise
( I-Premise
F I-Premise
( I-Premise
1 I-Premise
, I-Premise
24 I-Premise
) I-Premise
= I-Premise
5 I-Premise
. I-Premise
18 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
03 I-Premise
) I-Premise
, I-Premise
soundness I-Premise
of I-Premise
sleep I-Premise
( I-Premise
F I-Premise
( I-Premise
1 I-Premise
, I-Premise
24 I-Premise
) I-Premise
= I-Premise
9 I-Premise
. I-Premise
34 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
005 I-Premise
) I-Premise
, I-Premise
restored I-Premise
feeling I-Premise
upon I-Premise
awakening I-Premise
( I-Premise
F I-Premise
( I-Premise
1 I-Premise
, I-Premise
24 I-Premise
) I-Premise
= I-Premise
11 I-Premise
. I-Premise
95 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
002 I-Premise
) I-Premise
, I-Premise
and I-Premise
general I-Premise
fatigue I-Premise
( I-Premise
F I-Premise
( I-Premise
1 I-Premise
, I-Premise
26 I-Premise
) I-Premise
= I-Premise
13 I-Premise
. I-Premise
88 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
0 I-Premise
. I-Premise
001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
Although B-Premise
other I-Premise
group I-Premise
× I-Premise
time I-Premise
interactions I-Premise
were I-Premise
not I-Premise
significant I-Premise
, I-Premise
overall I-Premise
adjusted I-Premise
effect I-Premise
sizes I-Premise
for I-Premise
all I-Premise
sleep I-Premise
variables I-Premise
as I-Premise
well I-Premise
as I-Premise
for I-Premise
fatigue I-Premise
, I-Premise
depression I-Premise
, I-Premise
anxiety I-Premise
, I-Premise
and I-Premise
quality I-Premise
of I-Premise
life I-Premise
ranged I-Premise
from I-Premise
small I-Premise
to I-Premise
large I-Premise
. I-Premise
!LF! !LF!
CBT B-Claim
- B-Claim
I B-Claim
delivered I-Claim
through I-Claim
an I-Claim
interactive I-Claim
, I-Claim
individually I-Claim
tailored I-Claim
Internet I-Claim
intervention I-Claim
may I-Claim
be I-Claim
a I-Claim
viable I-Claim
treatment I-Claim
option I-Claim
for I-Claim
cancer I-Claim
survivors I-Claim
experiencing I-Claim
insomnia I-Claim
. I-Claim
!LF! !LF!
To O
compare O
the O
effectiveness O
and O
tolerability O
of O
gemcitabine O
plus O
cisplatin O
with O
single O
- O
agent O
gemcitabine O
as O
first O
- O
line O
chemotherapy O
for O
locally O
advanced O
or O
metastatic O
pancreatic O
cancer O
. O
!LF! !LF!
Patients O
with O
advanced O
adenocarcinoma O
of O
the O
pancreas O
were O
randomly O
assigned O
to O
receive O
either O
gemcitabine O
1 O
, O
000 O
mg O
/ O
m2 O
and O
cisplatin O
50 O
mg O
/ O
m2 O
given O
on O
days O
1 O
and O
15 O
of O
a O
4 O
- O
week O
cycle O
( O
GemCis O
arm O
) O
or O
gemcitabine O
alone O
at O
a O
dose O
of O
1 O
, O
000 O
mg O
/ O
m2 O
on O
days O
1 O
, O
8 O
, O
and O
15 O
of O
a O
4 O
- O
week O
regimen O
( O
Gem O
arm O
) O
. O
!LF! !LF!
The O
primary O
end O
point O
was O
overall O
survival O
"""" O
; O
"""" O
secondary O
end O
points O
were O
progression O
- O
free O
survival O
, O
response O
rate O
, O
safety O
, O
and O
quality O
of O
life O
. O
!LF! !LF!
One O
hundred O
ninety O
- O
five O
patients O
were O
enrolled O
and O
showed O
baseline O
characteristics O
well O
balanced O
between O
treatment O
arms O
. O
!LF! !LF!
Combination B-Premise
treatment I-Premise
in I-Premise
the I-Premise
GemCis I-Premise
arm I-Premise
was I-Premise
associated I-Premise
with I-Premise
a I-Premise
prolonged I-Premise
median I-Premise
progression I-Premise
- I-Premise
free I-Premise
survival I-Premise
( I-Premise
5 I-Premise
. I-Premise
3 I-Premise
months I-Premise
v I-Premise
3 I-Premise
. I-Premise
1 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
= I-Premise
0 I-Premise
. I-Premise
75 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
053 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
Also B-Premise
, I-Premise
median I-Premise
overall I-Premise
survival I-Premise
was I-Premise
superior I-Premise
for I-Premise
patients I-Premise
treated I-Premise
in I-Premise
the I-Premise
GemCis I-Premise
arm I-Premise
as I-Premise
compared I-Premise
with I-Premise
the I-Premise
Gem I-Premise
arm I-Premise
( I-Premise
7 I-Premise
. I-Premise
5 I-Premise
v I-Premise
6 I-Premise
. I-Premise
0 I-Premise
months I-Premise
) I-Premise
, I-Premise
an B-Premise
advantage I-Premise
which I-Premise
did I-Premise
not I-Premise
, I-Premise
however I-Premise
, I-Premise
reach I-Premise
statistical I-Premise
significance I-Premise
( I-Premise
HR I-Premise
= I-Premise
0 I-Premise
. I-Premise
80 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
15 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
Tumor B-Premise
response I-Premise
rates I-Premise
were I-Premise
comparable I-Premise
between I-Premise
treatment I-Premise
arms I-Premise
( I-Premise
10 I-Premise
. I-Premise
2 I-Premise
% I-Premise
v I-Premise
8 I-Premise
. I-Premise
2 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
The B-Premise
rate I-Premise
of I-Premise
stable I-Premise
disease I-Premise
was I-Premise
, I-Premise
however I-Premise
, I-Premise
greater I-Premise
in I-Premise
the I-Premise
combination I-Premise
arm I-Premise
( I-Premise
60 I-Premise
. I-Premise
2 I-Premise
% I-Premise
v I-Premise
40 I-Premise
. I-Premise
2 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
< I-Premise
. I-Premise
001 I-Premise
) I-Premise
. O
!LF! !LF!
Grade B-Premise
3 I-Premise
to I-Premise
4 I-Premise
hematologic I-Premise
toxicity I-Premise
did I-Premise
not I-Premise
exceed I-Premise
15 I-Premise
% I-Premise
in I-Premise
both I-Premise
treatment I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
These B-Claim
results I-Claim
support I-Claim
the I-Claim
efficacy I-Claim
and I-Claim
safety I-Claim
of I-Claim
an I-Claim
every I-Claim
- I-Claim
2 I-Claim
- I-Claim
weeks I-Claim
treatment I-Claim
with I-Claim
gemcitabine I-Claim
plus I-Claim
cisplatin I-Claim
. I-Claim
!LF! !LF!
Median B-Claim
overall I-Claim
survival I-Claim
and I-Claim
progression I-Claim
- I-Claim
free I-Claim
survival I-Claim
were I-Claim
more I-Claim
favorable I-Claim
in I-Claim
the I-Claim
combination I-Claim
arm I-Claim
as I-Claim
compared I-Claim
with I-Claim
gemcitabine I-Claim
alone I-Claim
, I-Claim
although B-Premise
the I-Premise
difference I-Premise
did I-Premise
not I-Premise
attain I-Premise
statistical I-Premise
significance I-Premise
. I-Premise
!LF! !LF!
Extracellular O
adenosine O
5 O
' O
- O
triphosphate O
( O
ATP O
) O
is O
involved O
in O
the O
regulation O
of O
a O
variety O
of O
biologic O
processes O
, O
including O
neurotransmission O
, O
muscle O
contraction O
, O
and O
liver O
glucose O
metabolism O
, O
via O
purinergic O
receptors O
. O
!LF! !LF!
In B-Claim
nonrandomized I-Claim
studies I-Claim
involving I-Claim
patients I-Claim
with I-Claim
different I-Claim
tumor I-Claim
types I-Claim
including I-Claim
non I-Claim
- I-Claim
small I-Claim
- I-Claim
cell I-Claim
lung I-Claim
cancer I-Claim
( I-Claim
NSCLC I-Claim
) I-Claim
, I-Claim
ATP I-Claim
infusion I-Claim
appeared I-Claim
to I-Claim
inhibit I-Claim
loss I-Claim
of I-Claim
weight I-Claim
and I-Claim
deterioration I-Claim
of I-Claim
quality I-Claim
of I-Claim
life I-Claim
( I-Claim
QOL I-Claim
) I-Claim
and I-Claim
performance I-Claim
status I-Claim
. I-Claim
!LF! !LF!
We O
conducted O
a O
randomized O
clinical O
trial O
to O
evaluate O
the O
effects O
of O
ATP O
in O
patients O
with O
advanced O
NSCLC O
( O
stage O
IIIB O
or O
IV O
) O
. O
!LF! !LF!
Fifty O
- O
eight O
patients O
were O
randomly O
assigned O
to O
receive O
either O
10 O
intravenous O
30 O
- O
hour O
ATP O
infusions O
, O
with O
the O
infusions O
given O
at O
- O
2 O
to O
4 O
- O
week O
intervals O
, O
or O
no O
ATP O
. O
!LF! !LF!
Outcome O
parameters O
were O
assessed O
every O
4 O
weeks O
until O
28 O
weeks O
. O
!LF! !LF!
Between O
- O
group O
differences O
were O
tested O
for O
statistical O
significance O
by O
use O
of O
repeated O
- O
measures O
analysis O
, O
and O
reported O
P O
values O
are O
two O
- O
sided O
. O
!LF! !LF!
Twenty O
- O
eight O
patients O
were O
allocated O
to O
receive O
ATP O
treatment O
and O
30 O
received O
no O
ATP O
. O
!LF! !LF!
Mean B-Premise
weight I-Premise
changes I-Premise
per I-Premise
4 I-Premise
- I-Premise
week I-Premise
period I-Premise
were I-Premise
- I-Premise
1 I-Premise
. I-Premise
0 I-Premise
kg I-Premise
( I-Premise
95 I-Premise
% I-Premise
confidence I-Premise
interval I-Premise
[ I-Premise
CI I-Premise
] I-Premise
= I-Premise
- I-Premise
1 I-Premise
. I-Premise
5 I-Premise
to I-Premise
- I-Premise
0 I-Premise
. I-Premise
5 I-Premise
) I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
and I-Premise
0 I-Premise
. I-Premise
2 I-Premise
kg I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
- I-Premise
0 I-Premise
. I-Premise
2 I-Premise
to I-Premise
+ I-Premise
0 I-Premise
. I-Premise
6 I-Premise
) I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
002 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
Serum B-Premise
albumin I-Premise
concentration I-Premise
declined I-Premise
by I-Premise
- I-Premise
1 I-Premise
. I-Premise
2 I-Premise
g I-Premise
/ I-Premise
L I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
- I-Premise
2 I-Premise
. I-Premise
0 I-Premise
to I-Premise
- I-Premise
0 I-Premise
. I-Premise
4 I-Premise
) I-Premise
per I-Premise
4 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
but I-Premise
remained I-Premise
stable I-Premise
( I-Premise
0 I-Premise
. I-Premise
0 I-Premise
g I-Premise
/ I-Premise
L I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
- I-Premise
0 I-Premise
. I-Premise
3 I-Premise
to I-Premise
+ I-Premise
0 I-Premise
. I-Premise
3 I-Premise
) I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
006 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
Elbow B-Premise
flexor I-Premise
muscle I-Premise
strength I-Premise
declined I-Premise
by I-Premise
- I-Premise
5 I-Premise
. I-Premise
5 I-Premise
% I-Premise
( I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
- I-Premise
9 I-Premise
. I-Premise
6 I-Premise
% I-Premise
to I-Premise
- I-Premise
1 I-Premise
. I-Premise
4 I-Premise
% I-Premise
) I-Premise
per I-Premise
4 I-Premise
weeks I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
but I-Premise
remained I-Premise
stable I-Premise
( I-Premise
0 I-Premise
. I-Premise
0 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
= I-Premise
- I-Premise
1 I-Premise
. I-Premise
4 I-Premise
% I-Premise
to I-Premise
+ I-Premise
1 I-Premise
. I-Premise
4 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
01 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
A B-Premise
similar I-Premise
pattern I-Premise
was I-Premise
observed I-Premise
for I-Premise
knee I-Premise
extensor I-Premise
muscles I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
02 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
The B-Premise
effects I-Premise
of I-Premise
ATP I-Premise
on I-Premise
body I-Premise
weight I-Premise
, I-Premise
muscle I-Premise
strength I-Premise
, I-Premise
and I-Premise
albumin I-Premise
concentration I-Premise
were I-Premise
especially I-Premise
marked I-Premise
in I-Premise
cachectic I-Premise
patients I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
0002 I-Premise
, I-Premise
P I-Premise
= I-Premise
. I-Premise
0001 I-Premise
, I-Premise
and I-Premise
P I-Premise
= I-Premise
. I-Premise
1 I-Premise
, I-Premise
respectively I-Premise
, I-Premise
for I-Premise
ATP I-Premise
versus I-Premise
no I-Premise
ATP I-Premise
) I-Premise
. I-Premise
!LF! !LF!
QOL B-Premise
score I-Premise
changes I-Premise
per I-Premise
4 I-Premise
- I-Premise
week I-Premise
period I-Premise
in I-Premise
the I-Premise
ATP I-Premise
group I-Premise
showed I-Premise
overall I-Premise
less I-Premise
deterioration I-Premise
than I-Premise
in I-Premise
the I-Premise
control I-Premise
group I-Premise
- I-Premise
physical I-Premise
scores I-Premise
( I-Premise
- I-Premise
0 I-Premise
. I-Premise
2 I-Premise
% I-Premise
versus I-Premise
- I-Premise
2 I-Premise
. I-Premise
4 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
2 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
functional I-Premise
scores I-Premise
( I-Premise
+ I-Premise
0 I-Premise
. I-Premise
4 I-Premise
% I-Premise
versus I-Premise
- I-Premise
5 I-Premise
. I-Premise
5 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
02 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
psychologic I-Premise
scores I-Premise
( I-Premise
- I-Premise
0 I-Premise
. I-Premise
7 I-Premise
% I-Premise
versus I-Premise
- I-Premise
2 I-Premise
. I-Premise
4 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
11 I-Premise
) I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
overall I-Premise
QOL I-Premise
score I-Premise
( I-Premise
+ I-Premise
0 I-Premise
. I-Premise
1 I-Premise
% I-Premise
versus I-Premise
- I-Premise
3 I-Premise
. I-Premise
5 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
0001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
This O
randomized O
trial O
demonstrates O
that O
ATP B-Claim
has I-Claim
beneficial I-Claim
effects I-Claim
on I-Claim
weight I-Claim
, I-Claim
muscle I-Claim
strength I-Claim
, I-Claim
and I-Claim
QOL I-Claim
in I-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
. I-Claim
!LF! !LF!
Abiraterone B-Claim
acetate I-Claim
plus I-Claim
prednisone I-Claim
significantly I-Claim
improves I-Claim
radiographic I-Claim
progression I-Claim
- I-Claim
free I-Claim
survival I-Claim
in I-Claim
asymptomatic I-Claim
or I-Claim
mildly I-Claim
symptomatic I-Claim
, I-Claim
chemotherapy I-Claim
- I-Claim
naive I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
castration I-Claim
- I-Claim
resistant I-Claim
prostate I-Claim
cancer I-Claim
compared I-Claim
with I-Claim
prednisone I-Claim
alone I-Claim
. I-Claim
!LF! !LF!
We O
describe O
analyses O
of O
data O
for O
patient O
- O
reported O
pain O
and O
functional O
status O
in O
a O
preplanned O
interim O
analysis O
of O
a O
phase O
3 O
trial O
. O
!LF! !LF!
Between O
April O
28 O
, O
2009 O
, O
and O
June O
23 O
, O
2010 O
, O
patients O
with O
progressive O
, O
metastatic O
castration O
- O
resistant O
prostate O
cancer O
were O
enrolled O
into O
a O
multinational O
, O
double O
- O
blind O
, O
placebo O
- O
controlled O
trial O
. O
!LF! !LF!
Patients O
were O
eligible O
if O
they O
were O
asymptomatic O
( O
score O
of O
0 O
or O
1 O
on O
item O
three O
of O
the O
Brief O
Pain O
Inventory O
Short O
Form O
[ O
BPI O
- O
SF O
] O
questionnaire O
) O
or O
mildly O
symptomatic O
( O
score O
of O
2 O
or O
3 O
) O
and O
had O
not O
previously O
received O
chemotherapy O
. O
!LF! !LF!
Patients O
were O
randomly O
assigned O
( O
1 O
: O
1 O
) O
to O
receive O
oral O
abiraterone O
( O
1 O
g O
daily O
) O
plus O
prednisone O
( O
5 O
mg O
twice O
daily O
) O
or O
placebo O
plus O
prednisone O
in O
continuous O
4 O
- O
week O
cycles O
. O
!LF! !LF!
Pain O
was O
assessed O
with O
the O
BPI O
- O
SF O
questionnaire O
, O
and O
health O
- O
related O
quality O
of O
life O
( O
HRQoL O
) O
with O
the O
Functional O
Assessment O
of O
Cancer O
Therapy O
- O
Prostate O
( O
FACT O
- O
P O
) O
questionnaire O
. O
!LF! !LF!
We O
analysed O
data O
with O
prespecified O
criteria O
for O
clinically O
meaningful O
pain O
progression O
and O
deterioration O
in O
HRQoL O
. O
!LF! !LF!
All O
patients O
who O
underwent O
randomisation O
were O
included O
in O
analyses O
. O
!LF! !LF!
1088 O
patients O
underwent O
randomisation O
: O
546 O
were O
assigned O
to O
abiraterone O
plus O
prednisone O
and O
542 O
to O
placebo O
plus O
prednisone O
. O
!LF! !LF!
At O
the O
time O
of O
the O
second O
prespecified O
interim O
analysis O
, O
median O
follow O
- O
up O
was O
22 O
· O
2 O
months O
( O
IQR O
20 O
· O
2 O
- O
24 O
· O
8 O
) O
. O
!LF! !LF!
Median B-Premise
time I-Premise
to I-Premise
progression I-Premise
of I-Premise
mean I-Premise
pain I-Premise
intensity I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
assigned I-Premise
to I-Premise
abiraterone I-Premise
plus I-Premise
prednisone I-Premise
( I-Premise
26 I-Premise
· I-Premise
7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
19 I-Premise
· I-Premise
3 I-Premise
- I-Premise
not I-Premise
estimable I-Premise
] I-Premise
) I-Premise
than I-Premise
in I-Premise
those I-Premise
assigned I-Premise
to I-Premise
placebo I-Premise
plus I-Premise
prednisone I-Premise
( I-Premise
18 I-Premise
· I-Premise
4 I-Premise
months I-Premise
[ I-Premise
14 I-Premise
· I-Premise
9 I-Premise
- I-Premise
not I-Premise
estimable I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
hazard I-Premise
ratio I-Premise
[ I-Premise
HR I-Premise
] I-Premise
0 I-Premise
· I-Premise
82 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0 I-Premise
· I-Premise
67 I-Premise
- I-Premise
1 I-Premise
· I-Premise
00 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
· I-Premise
0490 I-Premise
) I-Premise
, I-Premise
as I-Premise
was I-Premise
median I-Premise
time I-Premise
to I-Premise
progression I-Premise
of I-Premise
pain I-Premise
interference I-Premise
with I-Premise
daily I-Premise
activities I-Premise
( I-Premise
10 I-Premise
· I-Premise
3 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
9 I-Premise
· I-Premise
3 I-Premise
- I-Premise
13 I-Premise
· I-Premise
0 I-Premise
] I-Premise
vs I-Premise
7 I-Premise
· I-Premise
4 I-Premise
months I-Premise
[ I-Premise
6 I-Premise
· I-Premise
4 I-Premise
- I-Premise
8 I-Premise
· I-Premise
6 I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
HR I-Premise
0 I-Premise
· I-Premise
79 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0 I-Premise
· I-Premise
67 I-Premise
- I-Premise
0 I-Premise
· I-Premise
93 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
· I-Premise
005 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
Median B-Premise
time I-Premise
to I-Premise
progression I-Premise
of I-Premise
worst I-Premise
pain I-Premise
was I-Premise
also I-Premise
longer I-Premise
with I-Premise
abiraterone I-Premise
plus I-Premise
prednisone I-Premise
( I-Premise
26 I-Premise
· I-Premise
7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
19 I-Premise
· I-Premise
4 I-Premise
- I-Premise
not I-Premise
estimable I-Premise
] I-Premise
) I-Premise
than I-Premise
with I-Premise
placebo I-Premise
plus I-Premise
prednisone I-Premise
( I-Premise
19 I-Premise
· I-Premise
4 I-Premise
months I-Premise
[ I-Premise
16 I-Premise
· I-Premise
6 I-Premise
- I-Premise
not I-Premise
estimable I-Premise
] I-Premise
) I-Premise
, I-Premise
but I-Premise
the I-Premise
difference I-Premise
was I-Premise
not I-Premise
significant I-Premise
( I-Premise
HR I-Premise
0 I-Premise
· I-Premise
85 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0 I-Premise
· I-Premise
69 I-Premise
- I-Premise
1 I-Premise
· I-Premise
04 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
· I-Premise
109 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
Median B-Premise
time I-Premise
to I-Premise
HRQoL I-Premise
deterioration I-Premise
was I-Premise
longer I-Premise
in I-Premise
patients I-Premise
assigned I-Premise
to I-Premise
abiraterone I-Premise
plus I-Premise
prednisone I-Premise
than I-Premise
in I-Premise
those I-Premise
assigned I-Premise
to I-Premise
placebo I-Premise
plus I-Premise
prednisone I-Premise
as I-Premise
assessed I-Premise
by I-Premise
the I-Premise
FACT I-Premise
- I-Premise
P I-Premise
total I-Premise
score I-Premise
( I-Premise
12 I-Premise
· I-Premise
7 I-Premise
months I-Premise
[ I-Premise
95 I-Premise
% I-Premise
CI I-Premise
11 I-Premise
· I-Premise
1 I-Premise
- I-Premise
14 I-Premise
· I-Premise
0 I-Premise
] I-Premise
vs I-Premise
8 I-Premise
· I-Premise
3 I-Premise
months I-Premise
[ I-Premise
7 I-Premise
· I-Premise
4 I-Premise
- I-Premise
10 I-Premise
· I-Premise
6 I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
HR I-Premise
0 I-Premise
· I-Premise
78 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0 I-Premise
· I-Premise
66 I-Premise
- I-Premise
0 I-Premise
· I-Premise
92 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
= I-Premise
0 I-Premise
· I-Premise
003 I-Premise
) I-Premise
and I-Premise
by I-Premise
the I-Premise
score I-Premise
on I-Premise
its I-Premise
prostate I-Premise
- I-Premise
cancer I-Premise
- I-Premise
specific I-Premise
subscale I-Premise
( I-Premise
11 I-Premise
· I-Premise
1 I-Premise
months I-Premise
[ I-Premise
8 I-Premise
· I-Premise
6 I-Premise
- I-Premise
13 I-Premise
· I-Premise
8 I-Premise
] I-Premise
vs I-Premise
5 I-Premise
· I-Premise
8 I-Premise
months I-Premise
[ I-Premise
5 I-Premise
· I-Premise
5 I-Premise
- I-Premise
8 I-Premise
· I-Premise
3 I-Premise
] I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
HR I-Premise
0 I-Premise
· I-Premise
70 I-Premise
, I-Premise
95 I-Premise
% I-Premise
CI I-Premise
0 I-Premise
· I-Premise
60 I-Premise
- I-Premise
0 I-Premise
· I-Premise
83 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
p I-Premise
< I-Premise
0 I-Premise
· I-Premise
0001 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
Abiraterone B-Claim
plus I-Claim
prednisone I-Claim
delays I-Claim
patient I-Claim
- I-Claim
reported I-Claim
pain I-Claim
progression I-Claim
and I-Claim
HRQoL I-Claim
deterioration I-Claim
in I-Claim
chemotherapy I-Claim
- I-Claim
naive I-Claim
patients I-Claim
with I-Claim
metastatic I-Claim
castration I-Claim
- I-Claim
resistant I-Claim
prostate I-Claim
cancer I-Claim
. I-Claim
!LF! !LF!
These B-Claim
results I-Claim
provide I-Claim
further I-Claim
support I-Claim
for I-Claim
the I-Claim
efficacy I-Claim
of I-Claim
abiraterone I-Claim
in I-Claim
this I-Claim
population I-Claim
. I-Claim
!LF! !LF!
Postoperative B-Claim
adjuvant I-Claim
chemoradiation I-Claim
treatment I-Claim
after I-Claim
curative I-Claim
resection I-Claim
for I-Claim
rectal I-Claim
cancer I-Claim
was I-Claim
needed I-Claim
to I-Claim
reduce I-Claim
recurrence I-Claim
and I-Claim
improve I-Claim
a I-Claim
survival I-Claim
rate I-Claim
. I-Claim
!LF! !LF!
Intravenous B-Claim
5 I-Claim
- I-Claim
fluorouracil I-Claim
( I-Claim
5 I-Claim
- I-Claim
FU I-Claim
) I-Claim
and I-Claim
leucovorin I-Claim
has I-Claim
been I-Claim
a I-Claim
mainstay I-Claim
of I-Claim
chemotherapy I-Claim
, I-Claim
but O
oral B-Claim
5 I-Claim
- I-Claim
FU I-Claim
derivatives I-Claim
have I-Claim
been I-Claim
shown I-Claim
a I-Claim
comparable I-Claim
antitumor I-Claim
activity I-Claim
. I-Claim
!LF! !LF!
Intravenous O
5 O
- O
FU O
and O
oral O
doxifluridine O
were O
compared O
with O
respect O
to O
therapeutic O
efficacy O
, O
drug O
toxicity O
, O
and O
quality O
of O
life O
. O
!LF! !LF!
A O
total O
of O
166 O
patients O
were O
randomized O
to O
receive O
intravenous O
5 O
- O
FU O
( O
450 O
mg O
/ O
m2 O
/ O
day O
) O
or O
oral O
doxifluridine O
( O
900 O
mg O
/ O
m2 O
/ O
day O
) O
in O
combination O
with O
leucovorin O
( O
20 O
mg O
/ O
m2 O
/ O
day O
) O
for O
depth O
of O
invasion O
, O
nodal O
status O
, O
metastasis O
( O
TNM O
) O
stage O
II O
and O
III O
patients O
between O
October O
1997 O
and O
February O
1999 O
. O
!LF! !LF!
Consecutive O
daily O
intravenous O
infusion O
for O
5 O
days O
per O
every O
month O
for O
a O
total O
of O
12 O
cycles O
( O
IV O
arm O
, O
n O
= O
74 O
) O
and O
oral O
doxifluridine O
daily O
for O
3 O
weeks O
and O
1 O
week O
rest O
for O
a O
total O
of O
12 O
cycles O
( O
oral O
arm O
, O
n O
= O
92 O
) O
. O
!LF! !LF!
Drug O
toxicity O
and O
quality O
of O
life O
were O
observed O
. O
!LF! !LF!
Quality O
of O
life O
was O
scored O
according O
to O
22 O
daily O
activity O
items O
( O
good O
, O
> O
or O
71 O
"""" O
; O
"""" O
fair O
, O
< O
70 O
"""" O
; O
"""" O
poor O
, O
< O
52 O
) O
. O
!LF! !LF!
There O
was O
no O
difference O
of O
sex O
between O
two O
groups O
( O
IV O
arm O
: O
male O
/ O
female O
= O
45 O
/ O
29 O
, O
oral O
arm O
: O
male O
/ O
female O
= O
59 O
/ O
33 O
) O
. O
!LF! !LF!
The O
mean O
age O
was O
52 O
. O
3 O
vs O
. O
59 O
. O
5 O
, O
respectively O
. O
!LF! !LF!
There O
was O
also O
no O
difference O
of O
TNM O
stage O
distribution O
and O
type O
of O
operation O
between O
groups O
( O
P O
> O
. O
05 O
) O
. O
!LF! !LF!
Mean B-Premise
numbers I-Premise
of I-Premise
chemotherapy I-Premise
cycles I-Premise
were I-Premise
6 I-Premise
. I-Premise
5 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
3 I-Premise
. I-Premise
7 I-Premise
( I-Premise
IV I-Premise
arm I-Premise
) I-Premise
vs I-Premise
. I-Premise
7 I-Premise
. I-Premise
2 I-Premise
+ I-Premise
/ I-Premise
- I-Premise
4 I-Premise
. I-Premise
3 I-Premise
( I-Premise
oral I-Premise
arm I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
The B-Premise
rate I-Premise
of I-Premise
recurrence I-Premise
was I-Premise
9 I-Premise
/ I-Premise
74 I-Premise
( I-Premise
12 I-Premise
. I-Premise
1 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
IV I-Premise
arm I-Premise
and I-Premise
6 I-Premise
/ I-Premise
92 I-Premise
( I-Premise
6 I-Premise
. I-Premise
5 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
937 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
Local B-Premise
recurrence I-Premise
was I-Premise
2 I-Premise
/ I-Premise
74 I-Premise
( I-Premise
stage I-Premise
III I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
2 I-Premise
. I-Premise
7 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
IV I-Premise
arm I-Premise
and I-Premise
1 I-Premise
/ I-Premise
92 I-Premise
( I-Premise
stage I-Premise
II I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
1 I-Premise
. I-Premise
1 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
Systemic B-Premise
recurrence I-Premise
was I-Premise
7 I-Premise
/ I-Premise
74 I-Premise
( I-Premise
stage I-Premise
III I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
9 I-Premise
. I-Premise
4 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
IV I-Premise
arm I-Premise
and I-Premise
5 I-Premise
/ I-Premise
92 I-Premise
( I-Premise
stage I-Premise
III I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
5 I-Premise
. I-Premise
4 I-Premise
% I-Premise
) I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
The B-Premise
most I-Premise
common I-Premise
site I-Premise
of I-Premise
systemic I-Premise
recurrence I-Premise
was I-Premise
the I-Premise
liver I-Premise
. I-Premise
!LF! !LF!
Toxicity B-Premise
profile I-Premise
was I-Premise
as I-Premise
follows I-Premise
: I-Premise
leukopenia I-Premise
( I-Premise
30 I-Premise
/ I-Premise
74 I-Premise
vs I-Premise
. I-Premise
17 I-Premise
/ I-Premise
92 I-Premise
) I-Premise
and I-Premise
alopecia I-Premise
( I-Premise
21 I-Premise
/ I-Premise
74 I-Premise
vs I-Premise
. I-Premise
13 I-Premise
/ I-Premise
92 I-Premise
) I-Premise
were I-Premise
statistically I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
IV I-Premise
arm I-Premise
. I-Premise
!LF! !LF!
Diarrhea B-Premise
was I-Premise
more I-Premise
common I-Premise
in I-Premise
the I-Premise
oral I-Premise
arm I-Premise
. I-Premise
!LF! !LF!
Poor B-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
between I-Premise
two I-Premise
groups I-Premise
was I-Premise
observed I-Premise
at I-Premise
1 I-Premise
month I-Premise
( I-Premise
23 I-Premise
. I-Premise
9 I-Premise
% I-Premise
vs I-Premise
. I-Premise
13 I-Premise
% I-Premise
) I-Premise
and I-Premise
2 I-Premise
months I-Premise
( I-Premise
15 I-Premise
. I-Premise
8 I-Premise
% I-Premise
vs I-Premise
. I-Premise
3 I-Premise
. I-Premise
7 I-Premise
% I-Premise
) I-Premise
after I-Premise
chemotherapy I-Premise
. I-Premise
!LF! !LF!
Good B-Premise
quality I-Premise
of I-Premise
life I-Premise
score I-Premise
was I-Premise
observed I-Premise
at I-Premise
1 I-Premise
month I-Premise
( I-Premise
19 I-Premise
. I-Premise
5 I-Premise
% I-Premise
vs I-Premise
. I-Premise
49 I-Premise
% I-Premise
) I-Premise
and I-Premise
2 I-Premise
months I-Premise
( I-Premise
47 I-Premise
% I-Premise
vs I-Premise
. I-Premise
72 I-Premise
% I-Premise
) I-Premise
, I-Premise
respectively I-Premise
( I-Premise
P I-Premise
< I-Premise
. I-Premise
05 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
Oral B-Claim
doxifluridine I-Claim
with I-Claim
leucovorin I-Claim
shows I-Claim
a I-Claim
comparable I-Claim
therapeutic I-Claim
efficacy I-Claim
to I-Claim
intravenous I-Claim
5 I-Claim
- I-Claim
FU I-Claim
regimen I-Claim
with I-Claim
high I-Claim
quality I-Claim
of I-Claim
life I-Claim
as I-Claim
postoperative I-Claim
adjuvant I-Claim
therapy I-Claim
. I-Claim
!LF! !LF!
The B-Claim
oral I-Claim
regimen I-Claim
also I-Claim
can I-Claim
be I-Claim
safely I-Claim
given I-Claim
with I-Claim
appropriate I-Claim
toxicity I-Claim
and I-Claim
tolerability I-Claim
. I-Claim
!LF! !LF!
This O
phase O
III O
randomized O
trial O
compared O
two O
chemotherapy O
regimens O
, O
gemcitabine O
plus O
carboplatin O
and O
mitomycin O
, O
ifosfamide O
, O
and O
cisplatin O
, O
in O
chemotherapy O
- O
naive O
patients O
with O
advanced O
non O
- O
small O
- O
cell O
lung O
cancer O
( O
NSCLC O
) O
. O
!LF! !LF!
The O
regimens O
were O
compared O
with O
regard O
to O
effects O
on O
survival O
, O
response O
rates O
, O
toxicity O
, O
and O
quality O
of O
life O
. O
!LF! !LF!
Eligible O
patients O
had O
previously O
untreated O
stage O
IIIB O
or O
IV O
NSCLC O
suitable O
for O
cisplatin O
- O
based O
chemotherapy O
. O
!LF! !LF!
Randomly O
assigned O
patients O
were O
to O
receive O
four O
cycles O
, O
each O
at O
3 O
- O
week O
intervals O
, O
of O
carboplatin O
area O
under O
the O
curve O
of O
5 O
on O
day O
1 O
plus O
gemcitabine O
1 O
, O
200 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
and O
8 O
( O
GCa O
) O
or O
mitomycin O
6 O
mg O
/ O
m O
( O
2 O
) O
, O
ifosfamide O
3g O
/ O
m O
( O
2 O
) O
, O
and O
cisplatin O
50 O
mg O
/ O
m O
( O
2 O
) O
on O
day O
1 O
( O
MIC O
) O
. O
!LF! !LF!
Between O
February O
1999 O
and O
August O
2001 O
, O
422 O
patients O
( O
GCa O
, O
n O
= O
212 O
"""" O
; O
"""" O
MIC O
, O
n O
= O
210 O
) O
were O
randomly O
assigned O
in O
the O
United O
Kingdom O
. O
!LF! !LF!
The O
majority O
of O
patients O
received O
the O
intended O
four O
cycles O
( O
GCa O
, O
64 O
% O
"""" O
; O
"""" O
MIC O
, O
61 O
% O
) O
. O
!LF! !LF!
There B-Premise
was I-Premise
a I-Premise
significant I-Premise
survival I-Premise
advantage I-Premise
for I-Premise
GCa I-Premise
compared I-Premise
with I-Premise
MIC I-Premise
( I-Premise
hazard I-Premise
ratio I-Premise
, I-Premise
0 I-Premise
. I-Premise
76 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
0 I-Premise
. I-Premise
61 I-Premise
to I-Premise
0 I-Premise
. I-Premise
93 I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
008 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
Median B-Premise
survival I-Premise
was I-Premise
10 I-Premise
months I-Premise
with I-Premise
GCa I-Premise
and I-Premise
7 I-Premise
. I-Premise
6 I-Premise
months I-Premise
with I-Premise
MIC I-Premise
( I-Premise
difference I-Premise
, I-Premise
2 I-Premise
. I-Premise
4 I-Premise
months I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
1 I-Premise
. I-Premise
0 I-Premise
to I-Premise
4 I-Premise
. I-Premise
0 I-Premise
) I-Premise
, I-Premise
and I-Premise
1 I-Premise
- I-Premise
year I-Premise
survival I-Premise
was I-Premise
40 I-Premise
% I-Premise
with I-Premise
GCa I-Premise
and I-Premise
30 I-Premise
% I-Premise
with I-Premise
MIC I-Premise
( I-Premise
difference I-Premise
, I-Premise
10 I-Premise
% I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
95 I-Premise
% I-Premise
CI I-Premise
, I-Premise
3 I-Premise
% I-Premise
to I-Premise
18 I-Premise
% I-Premise
) I-Premise
. I-Premise
!LF! !LF!
Overall B-Premise
response I-Premise
rates I-Premise
were I-Premise
similar I-Premise
( I-Premise
42 I-Premise
% I-Premise
for I-Premise
GCa I-Premise
v I-Premise
41 I-Premise
% I-Premise
for I-Premise
MIC I-Premise
"""" I-Premise
; I-Premise
"""" I-Premise
P I-Premise
= I-Premise
. I-Premise
84 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
More B-Premise
thrombocytopenia I-Premise
occurred I-Premise
with I-Premise
GCa I-Premise
( I-Premise
P I-Premise
= I-Premise
. I-Premise
03 I-Premise
) I-Premise
, I-Premise
but B-Premise
this I-Premise
was I-Premise
not I-Premise
associated I-Premise
with I-Premise
increased I-Premise
hospital I-Premise
admission I-Premise
or I-Premise
fatality I-Premise
. I-Premise
!LF! !LF!
GCa B-Premise
caused I-Premise
less I-Premise
nausea I-Premise
, I-Premise
vomiting I-Premise
, I-Premise
constipation I-Premise
, I-Premise
and I-Premise
alopecia I-Premise
and I-Premise
was I-Premise
associated I-Premise
with I-Premise
fewer I-Premise
admissions I-Premise
for I-Premise
administration I-Premise
and I-Premise
better I-Premise
quality I-Premise
of I-Premise
life I-Premise
. I-Premise
!LF! !LF!
In B-Claim
patients I-Claim
with I-Claim
advanced I-Claim
NSCLC I-Claim
, I-Claim
GCa I-Claim
chemotherapy I-Claim
was I-Claim
shown I-Claim
to I-Claim
be I-Claim
a I-Claim
better I-Claim
- I-Claim
tolerated I-Claim
treatment I-Claim
that I-Claim
conferred I-Claim
a I-Claim
survival I-Claim
advantage I-Claim
over I-Claim
MIC I-Claim
. I-Claim
!LF! !LF!
To O
perform O
a O
randomized O
trial O
comparing O
70 O
and O
80 O
Gy O
radiotherapy O
for O
prostate O
cancer O
. O
!LF! !LF!
A O
total O
of O
306 O
patients O
with O
localized O
prostate O
cancer O
were O
randomized O
. O
!LF! !LF!
No O
androgen O
deprivation O
was O
allowed O
. O
!LF! !LF!
The O
primary O
endpoint O
was O
biochemical O
relapse O
according O
to O
the O
modified O
1997 O
- O
American O
Society O
for O
Therapeutic O
Radiology O
and O
Oncology O
and O
Phoenix O
definitions O
. O
!LF! !LF!
Toxicity O
was O
graded O
using O
the O
Radiation O
Therapy O
Oncology O
Group O
1991 O
criteria O
and O
the O
late O
effects O
on O
normal O
tissues O
- O
subjective O
, O
objective O
, O
management O
, O
analytic O
scales O
( O
LENT O
- O
SOMA O
) O
scales O
. O
!LF! !LF!
The O
patients O
' O
quality O
of O
life O
was O
scored O
using O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
Quality O
of O
Life O
Questionnaire O
30 O
- O
item O
cancer O
- O
specific O
and O
25 O
- O
item O
prostate O
- O
specific O
modules O
. O
!LF! !LF!
The O
median O
follow O
- O
up O
was O
61 O
months O
. O
!LF! !LF!
According O
to O
the O
1997 O
- O
American O
Society O
for O
Therapeutic O
Radiology O
and O
Oncology O
definition O
, O
the O
5 O
- O
year O
biochemical O
relapse O
rate O
was O
39 O
% O
and O
28 O
% O
in O
the O
- O
70 O
and O
80 O
- O
Gy O
arms O
, O
respectively O
( O
p O
= O
. O
036 O
) O
. O
!LF! !LF!
Using O
the O
Phoenix O
definition O
, O
the O
5 O
- O
year O
biochemical O
relapse O
rate O
was O
32 O
% O
and O
23 O
. O
5 O
% O
, O
respectively O
( O
p O
= O
. O
09 O
) O
. O
!LF! !LF!
The O
subgroup O
analysis O
showed O
a O
better O
biochemical O
outcome O
for O
the O
higher O
dose O
group O
with O
an O
initial O
prostate O
- O
specific O
antigen O
level O
> O
15 O
ng O
/ O
mL O
. O
!LF! !LF!
At O
the O
last O
follow O
- O
up O
date O
, O
26 O
patients O
had O
died O
, O
10 O
of O
their O
disease O
and O
none O
of O
toxicity O
, O
with O
no O
differences O
between O
the O
two O
arms O
. O
!LF! !LF!
According B-Premise
to I-Premise
the I-Premise
Radiation I-Premise
Therapy I-Premise
Oncology I-Premise
Group I-Premise
scale I-Premise
, I-Premise
the I-Premise
Grade I-Premise
2 I-Premise
or I-Premise
greater I-Premise
rectal I-Premise
toxicity I-Premise
rate I-Premise
was I-Premise
14 I-Premise
% I-Premise
and I-Premise
19 I-Premise
. I-Premise
5 I-Premise
% I-Premise
for I-Premise
the I-Premise
- I-Premise
70 I-Premise
and I-Premise
80 I-Premise
- I-Premise
Gy I-Premise
arms I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
22 I-Premise
) I-Premise
, I-Premise
respectively I-Premise
. I-Premise
!LF! !LF!
The B-Premise
Grade I-Premise
2 I-Premise
or I-Premise
greater I-Premise
urinary I-Premise
toxicity I-Premise
was I-Premise
10 I-Premise
% I-Premise
at I-Premise
70 I-Premise
Gy I-Premise
and I-Premise
17 I-Premise
. I-Premise
5 I-Premise
% I-Premise
at I-Premise
80 I-Premise
Gy I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
046 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
Similar B-Premise
results I-Premise
were I-Premise
observed I-Premise
using I-Premise
the I-Premise
LENT I-Premise
- I-Premise
SOMA I-Premise
scale I-Premise
. I-Premise
!LF! !LF!
Bladder B-Premise
toxicity I-Premise
was I-Premise
more I-Premise
frequent I-Premise
at I-Premise
80 I-Premise
Gy I-Premise
than I-Premise
at I-Premise
70 I-Premise
Gy I-Premise
( I-Premise
p I-Premise
= I-Premise
. I-Premise
039 I-Premise
) I-Premise
. I-Premise
!LF! !LF!
The B-Premise
quality I-Premise
- I-Premise
of I-Premise
- I-Premise
life I-Premise
questionnaire I-Premise
results I-Premise
before I-Premise
and I-Premise
5 I-Premise
years I-Premise
after I-Premise
treatment I-Premise
were I-Premise
available I-Premise
for I-Premise
103 I-Premise
patients I-Premise
with I-Premise
no I-Premise
differences I-Premise
found I-Premise
between I-Premise
the I-Premise
- I-Premise
70 I-Premise
and I-Premise
80 I-Premise
- I-Premise
Gy I-Premise
arms I-Premise
. I-Premise
!LF! !LF!
High B-Claim
- B-Claim
dose B-Claim
radiotherapy I-Claim
provided I-Claim
a I-Claim
better I-Claim
5 I-Claim
- I-Claim
year I-Claim
biochemical I-Claim
outcome I-Claim
with I-Claim
slightly I-Claim
greater I-Claim
toxicity I-Claim
. I-Claim
!LF! !LF!
Several O
multicomponent O
regimens O
have O
been O
reported O
to O
be O
useful O
in O
advanced O
androgen O
- O
independent O
prostate O
cancer O
. O
!LF! !LF!
We O
used O
a O
randomized O
phase O
II O
design O
to O
evaluate O
and O
compare O
two O
such O
regimens O
. O
!LF! !LF!
Patients O
were O
accrued O
primarily O
in O
the O
community O
setting O
. O
!LF! !LF!
Patients O
with O
progressive O
, O
androgen O
- O
independent O
prostate O
cancer O
were O
randomly O
assigned O
to O
one O
of O
two O
treatments O
: O
either O
ketoconazole O
/ O
doxorubicin O
alternating O
with O
vinblastine O
/ O
estramustine O
( O
KA O
/ O
VE O
) O
or O
paclitaxel O
, O
estramustine O
, O
and O
oral O
etoposide O
( O
TEE O
) O
. O
!LF! !LF!
